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 Cardiovascular diseases (CVDs) remain the number one cause of death 
worldwide, with yearly deaths expected to increase from 17.3 to 23.6 million by 
20301. Medical expenses associated with the treatment of CVD place a 
significant burden on the United States healthcare system. In 2010, CVD 
medication costs totaled $14.6 billion2. Poor compliance with CVD medication 
has gained attention as a driving factor of increased medical costs and 
preventable CVD-related deaths. Adherence to long-term prescribed CVD 
medications is as low as 50%3-5. Statin drugs, a group of lipid-lowering 
medication, are the most commonly prescribed CVD medication worldwide. 
Approximately 71% of individuals with CVD and 48% of individuals with 
hypercholesterolemia use cholesterol-lowering medication, with 93% of these 
medications being statins6. The monthly cost of statins can range from $4 to 
$600, depending on type, dose, and if a generic version is available7. Further, 
statin use can pose significant dose-dependent side effects. These include 
myalgia, as the most common side effect, as well as acute liver injury, hepatic 
steatosis, increased risk for development of Type II Diabetes, and cognitive 
impairments8. Side effects associated with statins are among the most common 
reasons for patients ceasing drug therapy9.  
 Currently, there is no optimal set of guidelines for prescribing statin drug 
therapy. The 2013 American College of Cardiology/American Heart Association 
(ACC/AHA) recommends initiation of statin treatment in patients with a 10-year 
global CVD-risk of 10% or greater, which 10-year risk being based on age, 
gender, ethnicity, blood pressure, current treatment with antihypertensive 
medication, and presence of diabetes or smoking behaviors10. The 2016 United 
States Prevention Services Task Force (USPSTF) guidelines also recommend a 
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10-year global CVD-risk of 10% or greater, as well as patients having one or 
more CVD risk factor (hypertension, dyslipidemia, smoking, diabetes). The gap in 
these conflicting guidelines could leave 9.3 million Americans untreated if one 
was fully adopted over the other11. Thus, current pharmacological therapies used 
for the prevention and treatment of CVD are costly, burdensome, have 
associated health risks, and current guidelines could leave patients untreated.  
 Implementing lifestyle therapies, including dietary modification, could 
improve CVD-outcomes, possibly reduce burden associated with medication 
adherence, and contribute to a healthier aging population. Current 
recommendations for treatment and prevention of CVD include statin therapy and 
adoption of a low-fat diet, such as the National Cholesterol Education 
Program/American Heart Association Step I or Step II diets. These dietary 
patterns recommend a reduction of total fat (<30% of calories), saturated fat 
(10% and <7% total calories), and dietary cholesterol (300 and 200mg daily). 
This recommendation is consistent with evidence that a reduction in exogenous 
fatty acids will, in turn, reduce the need to clear chylomicrons during lipoprotein 
metabolism, since higher chylomicron levels may promote atherogenesis12. 
Therefore, low-fat diets work by controlling exogenous sources of fats, and are 
often paired with statin drugs, which control cholesterol at an endogenous level.  
 Statin drugs, also known as HMG-CoA reductase inhibitors, gained 
popularity in the 1990’s, as knowledge of “good” and “bad” cholesterol became 
more widespread. Statin drugs became standard treatment for high dyslipidemia 
following publication of the Scandinavian Simvastatin Survival Study (4S study) 
in 1994. This secondary prevention, randomized, double blind, placebo-control 
trial investigated long-term use of simvastatin to reduce total mortality and 
coronary events in 4444 post-myocardial infraction (MI) and angina pectoris 
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patients with total cholesterol levels between 212 and 309mg/dL. The trial found 
a 42% reduction in cardiac mortality, as well as 38% reduction in LDL and 28% 
reduction in total cholesterol over the 6-year follow-up period13. This landmark 
trial contributed a great body of support for statins in preventing cardiovascular 
death through lowering total and LDL cholesterol levels. 
 In the same year, French cardiologist Dr. Michel de Lorgeril published his 
findings of the Lyon Diet Heart Study. Similarly to the 4S Study, the Lyon Diet 
Heart Study was a randomized, secondary prevention trial in 605 post-MI 
patients. The study compared the effects of an alpha-linolenic acid-rich 
Mediterranean diet (n=302) to a typical French diet (n=303), which is similar to 
Western diets in fat quality and content. The study evaluated differences in 
primary, secondary and tertiary endpoints, such as cardiac deaths, non-fatal MI, 
and overall mentality over a planned 5-year study period. The trial was halted 
after 27 months due to the Mediterranean diet group having a 50 to 70% lower 
risk of recurrent cardiac events compared to the control. This study was the first 
to provide evidence that questioned the lipid hypothesis due to finding no 
difference in serum lipids from baseline in the Mediterranean diet group14. 
 The developing body of literature on the Mediterranean diet over the past 
60 years has challenged the low-fat diet, showing more favorable reductions in 
serum lipids, as well as mortality risk, with the adoption of a Mediterranean diet. 
The Mediterranean Diet was first recognized for its cardioprotective benefits by 
Minnesota physiologist Ancel Keys in the Seven Countries Study. Keys found 
significantly lower rates of cardiovascular disease in countries surrounding the 
Mediterranean Sea15. The Mediterranean Diet emphasizes the following: high 
consumption of locally sourced plant-based foods, such as fruits, vegetables, 
whole grain breads, nuts, and legumes; olive oil as the main source of dietary fat; 
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moderate red wine consumption (one drink each day for women, two drinks each 
day for men); twice weekly fish consumption; low to moderate intake of dairy; and 
up to seven eggs per week; limited consumption of red and processed meats to 
once or twice per month. 
 Since it’s discovery, the beneficial role of the Mediterranean Diet has 
been largely studied. Both short- and long-term benefits of the diet have been 
established. One of the most notable studies to date is the Prevención con la 
Dieta Mediterránea (PREDIMED) trial, which investigated the role of the 
Mediterranean diet in primary prevention of Cardiovascular Disease. The study 
evaluated the effects in subjects randomized to a Mediterranean diet 
supplemented with olive oil or mixed nuts, or a low-fat diet. The PREDIMED trial 
found an energy-unrestricted Mediterranean diet, supplemented with nuts or 
extra-virgin olive oil, resulted in a 30% risk-reduction in major CVD events in 
subjects at high-risk for CVD compared to the low-fat diet control. The study also 
found decreased markers of inflammation (CRP, IL-6, IL-7), total serum 
cholesterol, body weight, plasma glucose, insulin resistance, development of 
type 2 diabetes, and an improvement in endothelial function16.  
 Although Mediterranean diet intervention trials continue to show the 
beneficial effects of the dietary pattern, statin drugs and low-fat diets continue to 
be most commonly prescribed regimen for the prevention and treatment of CVD. 
Recent meta-analyses on the Mediterranean diet have found significantly 
lowered triglycerides, LDL, and total cholesterol compared to low-fat diet control 
groups, as well as a positive association between length of intervention and 
improvement in HDL-cholesterol17.  
 There is sufficient literature examining the lipid-lowering ability of the 
Mediterranean diet, with many of these studies noting participants taking statin 
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drugs. No meta-analysis has evaluated the moderating effects of statin drug 
therapy in the relationship between the Mediterranean diet and serum lipids. A 
meta-analysis of existing randomized control studies would provide evidence on 
whether statin drugs provide additional beneficial effects in improving blood 
lipids, or if the changes observed are a result of the Mediterranean diet alone. 
Further, no meta-analysis has compared the effects of the Mediterranean diet to 
a low-fat diet with statins on serum lipids. This can allow for reduced CVD 
mortality, reduced individual prescription and health care costs, more 
individualized nutrition recommendations for individuals with dyslipidemia, and 
clarification on the role of diet in the lipid hypothesis.  
 Thus, research questions for the meta-analysis include: 1) Are the lipid-
lowering effects of the Mediterranean diet moderated by statin drug therapy in 
adults who are at high-risk or with existing Cardiovascular Disease (CVD)? 2) 
Does the Mediterranean diet produce greater improvements in serum lipid levels 
than a low-fat diet in adults at-risk and with existing cardiovascular disease? 3) Is 
the Mediterranean diet as effective as a low-fat diet with statin drugs in improving 
serum lipids in adults? The purpose of this thesis was to conduct a high-quality 
meta-analysis to evaluate the effects on statin drugs in the relationship between 
the Mediterranean diet and serum lipids, compare the effects of the 
Mediterranean diet to those of a low-fat diet on serum lipids, and to compare the 
effects of the Mediterranean diet to those of a low-fat diet with statin drugs. The 
specific aims are: 1) To evaluate the impact of the Mediterranean diet on serum 
lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) in adults 
at high-risk and with existing CVD, 2) to evaluate the moderating effect of statin 
drug therapy on the relationship between the Mediterranean diet and serum 
lipids, 3) compare the effects of a Mediterranean diet to those of a low-fat diet on 
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serum lipids, and 4) compare the effects of the Mediterranean diet to the low-fat 
diet with statins on serum lipids in adults at-risk and with existing CVD. The 
primary hypothesis is statin drugs will not be a significant moderator in the 
relationship between the Mediterranean diet and serum lipid levels. The null 
hypothesis states that the addition of statin drugs will have an effect on the 
relationship between the Mediterranean diet and improvement in serum lipids. 
The secondary hypothesis is the Mediterranean diet will provide greater 
improvements in serum lipid levels than a low-fat diet, with the null hypothesis 
stating there would be no difference in improvements observed among serum 
lipids between the low-fat and Mediterranean diet low-fat diet. Our third 
hypothesis is the Mediterranean diet will be equally effective in improving serum 
lipids compared to the traditionally prescribed low-fat diet and statin drug therapy 
combination. The null hypothesis for this hypothesis is the Mediterranean diet will 
not be equally effective as the low-fat diet and statins in their abilities to lower 




 To adequately compare the Mediterranean and low-fat diets, two 
separate literature searches were performed. Peer-reviewed literature articles 
were obtained following the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement guidelines18. Comprehensive 
literature searches were conducted using seven computer databases: PubMed 
(MEDLINE), EMBASE via Scopus, CINAHL, PsycINFO, Academic Search 
Premier, Agricola, and CAB Direct. The University of Connecticut Health 
Sciences Librarian (JL) assisted in the search. No language or date restriction 
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was used. For the Mediterranean diet, original research articles published until 
September 22, 2016 were included. A combination of key words and Medical 
Subject Headings related to the study were used. Examples of search terms 
included: “Mediterranean diet,” “Mediterranean-style diet,” “cardiovascular 
disease,” “hyperlipidemia,” “dyslipidemia,” “hydroxymethylglutaryl-coa reductase 
inhibitors”, “antihyperlipidemic medication,” “statin*,” and “Simvastatin.” The 
comprehensive search, with all terms, can be found in Appendix 1. The low-fat 
diet search also had no language or date restriction, and included published 
articles through October 7, 2016. The search terms differed in that instead of 
using Mediterranean diet-related words, examples include: “low fat,” “reduced 
fat,” “American Heart Association AND diet,” “therapeutic lifestyle changes AND 
diet,” “DASH,” “hypolipidemic,” and other related terms and phrases. These 
search terms can be found in Appendix 2. 
 Inclusion criteria stated the Mediterranean diet, as a whole dietary 
pattern,  must have been at least one of the interventions in the study. The study 
must have pre-test and post-test data for at least one of the outcome variables of 
interest: triglycerides, low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein (HDL) cholesterol, or total cholesterol. Due to this being a new area of 
research, an inadequate number of studies have analyzed the Mediterranean 
diet with statin drugs as part of an intervention. Therefore, the studies did not 
need statin medication as part of an intervention, but did need to report the 
percentage or number of subjects taking statin drugs in-text or in a table, such as 
one for demographic information. No minimum or maximum percentage of 
participants on statin drugs was placed for the study to be included. If a study 
met all criteria, but did not report statins in demographic information, one 
researcher (MC) contacted the provided study correspondence to inquire if the 
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data were available. Participants needed to be high-risk or with existing 
cardiovascular disease. High-risk subjects were defined as individuals with Type 
2 Diabetes Mellitus, or with at least 3 cardiovascular disease risk factors, 
including: elevated LDL-cholesterol (>160mg/dL), low HDL-cholesterol 
(<40mg/dL), Hypertension (>140mmHG/>90mmHG), overweight/obesity (BMI 
>25kg/m2), current smoking behaviors, or a family history of premature coronary 
heart disease. If studies were secondary analyses of other trials (i.e. PREDIMED 
substudies), they needed to have different sample sizes and be conducted at 
different locations to ensure the same data was not being accounted for twice. All 
studies needed to be experimental or Quasi-experimental in design. Exclusion 
criteria included studies with only pre-test or only post-test data, studies using 
statin drugs that were not/pending approval by the United States Food and Drug 
Administration, trials that allowed use of dietary supplements, interventions that 
only examined one component of the Mediterranean diet (only red wine, only 
olive oil, etc.), and non-intervention trials, trials with exercise as part of the 
intervention. Studies on subjects with Renal Disease or HIV/AIDS were also 
excluded due to the disease state requiring very restricted dietary guidelines and 
the disease-associated lipodystrophy.  
 For the low-fat diet search, inclusion criteria only differed in that one of 
the interventions must have been a low-fat diet, defined as <30% of total calories 
from fat, with statin drug therapy, at any dosage, with the low-fat diet as at least 
one of the interventions. All systematic reviews and meta-analyses found through 






 A 5-page, 330-item coding form, along with coding manual, created by a 
team of 3 Registered Dietitians, and physician, and biostatistician, was used to 
extract information from each included study. Examples of items coded for 
included: study information, such as study publication year, year of data 
collection, and journal name; population risk characteristics, such as age, 
disease state, and medication use; methods and design, including experimental 
conditions, and diet intervention characteristics. Two researchers (MC and JS) 
independently coded each article. A third part expert (TBHM) was consulted to 
settle disagreements and discrepancies between the independent researchers. 
Appendix 3 contains the coding form used for data extraction in this meta-
analysis. 
Risk of Bias 
 The Cochrane Collaboration’s tool was used to assess bias within 
individual studies. This tool uses a minus sign (“-“) to indicate a high risk of bias, 
a plus sign (“+”) to indicate moderate risk of bias, and two plus signs (“++”) to 
indicate low risk of bias for the parameter being evaluated. Various parameters 
were used to assess risk of the individual studies, such as subject level of 
randomization, subject and researcher blinding to intervention, report of attrition, 
and selective reporting. Methodological quality (MQ) has been identified as an 
under-reported element in the results of meta-analyses19. Methodological quality 
score was calculated using a 17-question, 22-point methodological quality control 
form, created from combining methodological quality rating scales published by 
Miller20 and Jadad21. This form can be found in Appendix 4. This meta-analysis 




 All descriptive statistics of the study populations were calculated using 
SAS version 9.422. These included total number of participants, percentage of 
male and female participants, mean age of subjects, and range and mean year of 
publication, among others. All code for the analysis can be found in Appendix 5. 
Inter-rater reliability (IRR) 23, which assesses the rate of agreement between the 
two coders as a proportion, was calculated using IBM SPSS Statistics Version 
2224. Categorical variables were calculated using Kappa coefficient25, and 
continuous variables were calculated using Pearson’s R23.  
 A standard mean effect size was calculated for each variable of interest in 
each study using an Excel coding calculator that uses a factor to control for small 
sample size26. The standard mean change, d, is the difference between the pre-
test and post-test means for a variable in a sample, divided by the pre-test 
standard deviation27. This allows for results of different study designs to be 
compared, regardless of the unit of measurement used in the individual studies. 
The standard mean difference follows a normal distribution, with zero as the null 
value. The effect is assessed using Cohen’s Classification, which interprets 0.25 
as a small effect, 0.5 s a medium effect, and 0.8 or higher as a large effect28. 
 The remaining statistical analysis was conducted in R version 3.3.1. 29 
using the ‘metafor’ package30, which is the package for meta-analysis in the R 
program. Weighted means were calculated using random-effects and fixed-
effects models, because they allow some studies to carry more weight in the 
analysis than others. Random-effects and fixed-effects models are used because 
they make different assumptions about the nature of the studies. Random-effects 
models control for sample size and variance, and assume all the data come from 
different populations. Fixed-effects models assume the data come from the same 
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population, and do not account for variance between studies31. Heterogeneity 
was assessed to consider the extent of consistency among the results27, and was 
evaluated with Cochran’s Q and I2. Two tests are used for heterogeneity because 
the Q statistic has low power in meta-analyses with few included studies or small 
sample size, or may carry too much power if there are many studies included. 
The Q statistic tests for significance of heterogeneity32, and I2 tests for magnitude 
of heterogeneity with a range of 0-100%31. An I2 value of 0 to 40% suggests 
heterogeneity observed may not be important, 30 to 60% represents there may 
be moderate heterogeneity, 50 to 90% represents there may be substantial 
heterogeneity, and 75 to 100% means there is considerable heterogeneity 
observed33. Publication bias was computed, which is used to evaluate how 
representative the samples in the studies are of the population by regressing the 
standard errors with the estimated models. This was measured with four 
statistical tests: two inferential tests, Begg34 and Egger35 and two graphical tests, 
trim-and-fill36 and a funnel plot37.  
 Moderator analysis was used to explain the significant amount of 
heterogeneity observed among the studies. A moderator is a third variable that 
alters the relationship of the independent and dependent variables. If the 
moderator variable is significant, it can strengthen or weaken the relationship 
between the independent and dependent variables. Moderators can be 
categorical or continuous variables. In this analysis, proportion of participants 
using statin drugs was used as a moderator to evaluate if the drug provided a 
significant improvement in any of the variables of interest (LDL-cholesterol, HDL-
cholesterol, triglycerides, total cholesterol) when used in combination with a 
Mediterranean diet. Other variables that at least 5 studies reported information 
on were evaluated as moderators to explain heterogeneity observed among the 
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studies. Variables evaluated as possible moderators included: a diagnosis of 
CVD or having cardiovascular risk factors, such as Hypertension, Dyslipidemia, 
or Type 2 Diabetes Mellitus, current smoking behaviors, being female, and 
weight status. Differences in study characteristics, such as intervention group 
size, sample size, level of supervision in trials, number of follow-ups, and length 
of study intervention, as well as region in which the study was conducted were 
also tested as moderator variables according to justification in the scientific 
literature17. Dietary intervention characteristics, such as recommended 
macronutrient distribution, intake of dietary cholesterol and saturated fats, dietary 
fiber, and sodium intake were also evaluated. The Moving Constant Technique38 
was used to create estimates and confidence intervals at multiple levels of the 
moderators, as well as confidence bands around the entire meta-regression line, 
to evaluate the effects of the dietary pattern further. All syntax for statistical 
analysis conducted in R can be found in Appendix 6 for the Mediterranean diet 
studies, and Appendix 7 for the low-fat diet studies. 
Results 
Literature Search 
 Inter-rater reliability resulted in a kappa coefficient of 0.93, with 96% 
agreement between coders for the Mediterranean diet studies, and 0.96 with 
96% agreement for coding of low-fat diet studies. A Pearson’s coefficient of r=1.0 
was obtained for continuous variables for both the Mediterranean diet and low-fat 
diet studies. The initial Mediterranean diet literature search provided 1,265 
articles, after removal of duplicate publications. Additionally, all systematic 
reviews and meta-analyses found through the literature search were hand-
searched to verify all relevant publications were included39-47, resulting in two 
additional articles being accepted for inclusion in the study that were not found 
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through the literature search. Studies were evaluated based on title, key words, 
and abstract by two independent researchers (MC and JS). The screening 
process eliminated 1199 articles. Full-text articles were obtained for the 
remaining 66 articles. After reviewing full-text articles against inclusion criteria, 54 
articles were excluded for reasons of not including statin drug information, 
exercise as a part of the intervention or placing a calorie restriction on the 
intervention groups. Six researchers were contacted at this step by email to 
request data on proportion of subjects taking statin drugs48-54, which resulted in 
exclusion of five of these 54 studies. The remaining 12 articles were accepted for 
analysis. For the low-fat diet search, 580 articles were found, after removal for 
duplicates. The screening process eliminated 543 articles. The remaining 37 full-
text articles were obtained. Upon full-text review, an additional 16 articles were 
excluded for reasons of not reporting pre-and post-intervention data, not having a 
low-fat diet intervention, and studies with children/adolescents. The remaining 21 
articles were accepted for analysis. All systematics reviews and meta-analyses 
found in the low-fat diet literature search were also hand-searched for possible 
inclusion55-82. One additional article was identified83, for a final count of 22 articles 
being accepted for analysis. 
Descriptive Statistics 
 Twelve Mediterranean diet studies, with a total of 9,882 subjects with a 
mean age of 61.75±7.82 years, were analyzed. Females accounted for 50.4% of 
the subjects. Further, 38.4% of subjects reported taking some type of statin 
medication during the trials, and 19.5% were current smokers. A total of 7,720 
(78.1%) subjects had hypertension, and 46.2% had dyslipidemia. Trial length 
ranged from 8 to 260 weeks. Mean publication year was 2007, with a range of 
1993-2016. The average impact factor of the journals of publication was 10.057. 
14 	
Seven of the studies were performed in European countries, and one was 
conducted in each the United States, Australia, and Asia. All reports were 
published in the English language. Four slight variations of the Mediterranean 
diet were observed: Traditional Mediterranean Diet, Indo-Mediterranean Diet, 
Mediterranean Diet with subjects provided extra-virgin olive oil, and 
Mediterranean Diet with subjects provided a mixed variety of nuts. A table of the 
Mediterranean diet intervention descriptive statistics can be found in Table 1. No 
significant asymmetries were found using the graphical and inferential tests. 
Publications bias values are displayed in Table 2. The average methodological 
quality score of studies was 13.15 with a range of 8 to 17. 
 Analysis of the 22 low-fat diet trials revealed a total of 6,793 subjects, 
57.7% of which were female. For CVD risk factors, a total of 9.6% of subjects 
were smokers, 22.7% carried a diagnosis of hypertension, and 72.6% of subjects 
had dyslipidemia. Trials had an average publication year of 1997, with a range of 
1990 to 2008. Studies were conducted in various countries, with 9 in the United 
States, 9 in European countries, 3 in Asia, 1 in Australia, 1 in Canada, and 1 in 
South America. The average impact factor of journals in which the studies were 
published was 9.636. Length of intervention ranged from 3 to 208 weeks. The 
studies used various forms of a low-fat diet intervention. Types of low-fat diets 
used in the interventions included: 10 low-fat diets, 6 American Heart Association 
Step 1 diets, 6 American Heart Association Step 2 diets, and 8 other variations, 
described as very low-fat, cholesterol-lowering, low saturated fat, lipid-lowering, 
and LifeSpring diets. All low-fat diets recommended no more than 30% of 
calories from fat, and as low as 17%. Intervention groups of the trials used 
various types of statins, including: 12 simvastatin, 8 lovastatin, 3 pravastatin, 3 
atorvastatin, 2 fluvastatin, and 1 rosuvastatin intervention. All low-fat descriptive 
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statistics can be viewed in Table 3. There were no significant asymmetries found 
in the inferential and graphical tests for publication bias. Publication bias results 
for the low-fat diet studies can be found in Table 4. Further, the average 
methodological quality score of studies was 12.23 with a range of 5 to 16. 
Random Effects Sizes 
  When individuals adopted a Mediterranean diet, there was a significant 
improvement in all outcomes (dTG = -0.45 [-0.79, -0.12, dChol = -0.66 [-0.96, -0.35, 
dLDL = -0.52 [-0.76, -0.27],], dHDL = 0.24 [0.01, 0.46]) shown by random effects 
model analysis. For heterogeneity, Cochran’s Q ranged from 74.24 to 224.42, 
and I2 ranged from 91.84 to 96.89%. A full table of these results can be found in 
Table 5. Adopting a low-fat diet resulted in significant reductions for total and 
LDL cholesterol (dTG = -0.12 [-0.25, 0.02], dChol = -0.39 [-0.57, -0.20], dLDL = -0.24 
[-0.36, -0.11], dHDL = 0.06 [-0.27, 0.16]). Cochran’s Q ranged from 70.92 to 
183.94 and I2 from 79.47% to 95.01%. Low-fat diet with statin drug therapy 
resulted in significant reductions for all serum lipid outcomes (dTG = -0.43 [-0.57, -
0.30], dTChol = -1.68 [-1.90, -1.46],  dLDL = -1.75 [-2.01, -1.49]), dHDL = 0.37 [0.29, 
0.45]). Cochran’s Q ranged from 299.10 to 723.97, and I2 ranged from 84.32 to 
96.75% A table of low-fat diet results, both with and without statin drugs, can be 
found in Table 6.  
Mediterranean Diet Moderator Analysis 
 Studies included in the analysis varied in study and intervention 
characteristics, such as study region, proportion of female subjects, length of 
intervention, and proportion of subjects with cardiovascular disease and 
cardiovascular disease risk factors, among others. Analysis of the proportion of 
subjects taking statin drugs with a Mediterranean diet intervention did not 
account for any heterogeneity across all four serum lipid variables (R2TChol = 
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0.00%, p= 0.95; R2TG = 0.00%, p=0.80; R2LDL = 0.00%, p = 0.47; R2HDL = 1.67%, p 
= 0.33). A predictive model was used to determine the magnitude of effect statin 
drugs carried with various proportions of subjects taking statins. The proportions 
analyzed included: 0%, 7% (minimum observed), 10%, 25%, 50%, 75%, and 
100% (maximum observed) of subjects. There were no significant associations 
observed for proportion of subjects and any of the serum lipid outcomes.  
 Across the interventions, a significant association was found between 
decrease in triglycerides and studies conducted in a European country (R2TG = 
32.00%, p=0.02), and with a greater number of follow-up sessions (R2TG = 
70.30%, p<.0001). The level of intervention supervision also accounted for 
significant heterogeneity for only triglyceride lowering - conducting one-on-one 
intervention sessions accounted for 32.00% of heterogeneity (p=0.02), and small 
group interventions for 28.16% (p=0.03) of the heterogeneity. Number of 
participants lost to follow-up accounted for the highest amount of heterogeneity 
for triglycerides (R2TG = 96.47%, p<.0001), but was not significant for any other 
outcomes of interest. 
Length of intervention (in weeks) had a significant impact on reduction in 
total cholesterol levels (R2TChol = 54.74%, p=0.02). A predictive model was used 
to determine the magnitude of effect for length of intervention at the minimum 
and maximum length (8 and 260 weeks). There was a significant association 
found for length of intervention and total cholesterol (BTChol = -0.003, p=0.02) – 
longer Mediterranean diet interventions resulted in greater decreases in total 
cholesterol. Receiving funding from a government source also was significantly 
associated with decrease in total cholesterol (R2TChol = 42.96%, p=0.01), and 
increase in HDL-cholesterol (R2LDL = 61.22%, p=0.0005).  
17 	
Carrying a diagnosis of dyslipidemia was associated with a significant 
beneficial effect on HDL cholesterol with consumption of a Mediterranean diet, 
explaining 81.20% (p<.0001) of the variability between studies. Studies reporting 
subjects taking hypoglycemic agents, such as insulin or oral hypoglycemic 
agents, explained heterogeneity for triglycerides and HDL (R2TG = 78.57%, 
p<.0001, R2HDL = 96.47%, p<.0001), but only trending towards significance for 
total cholesterol (R2TChol = 31.11%, p=0.10). Studies reporting subjects taking 
blood pressure medication during the trial explained some of the heterogeneity 
observed for LDL-cholesterol (R2LDL = 14.03%, p=0.03), with no other variables 
with adequate reported information explaining heterogeneity for this outcome. 
Other cardiovascular disease risk factors (e.g. hypertension, current 
smokers, being female, and weight loss) impact per publication (IPP) score of 
journal of publication, and methodological quality score were assessed and did 
not provide significant results. A full list of the Mediterranean diet moderator 
analysis results can be found in Table 7. 
Low-Fat Diet Moderator Analysis 
 Similar moderators evaluated for the Mediterranean diet were considering 
for the low-fat diet. Length of intervention was only found to be a significant 
moderator for triglycerides, explaining 31.86% (p=0.04) of the heterogeneity 
observed. Studies region was evaluated as a moderator, with sufficient data to 
evaluate studies conducted in the United States and in Europe. There was no 
association found between conducting a study in Europe with the low-fat diet for 
any of the four serum lipids; however, studies conducted in the United States 
explained 22.71% of the heterogeneity observed for total cholesterol p=0.03). 
Sample size also explained significant heterogeneity for total cholesterol 
(R2=32.80%, p=0.04). No other study characteristics were found to be significant. 
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 Cardiovascular disease and risk factors were also assessed. Both 
proportion and number of subjects with hypertension explained heterogeneity 
among the lipid outcomes. Proportion of subjects explained 59.12% (p=0.0007) 
of the variability observed for triglycerides, while number of subjects explained 
significant heterogeneity for total and LDL cholesterol (R2TChol =36.21%, p=0.048; 
R2LDL=78.06%, p=0.02). Female subjects also significant explained heterogeneity 
for total cholesterol (R2=34.79%, p=0.04). 
 Dietary characteristics were assessed to evaluate the impact of diet in the 
relationship between a low-fat diet and the four serum lipids. Macronutrient 
distribution was assessed and each macronutrient had significantly explained 
some of the heterogeneity for at least one serum lipid. Proportion of fat intake 
was significant for total cholesterol and LDL cholesterol (R2TChol =33.73%, 
p=0.0008; R2LDL=27.57%, p=0.0049), while proportion of protein intake was 
significant for HDL (R2=14.43%, p=0.04) and carbohydrate intake was significant 
for triglycerides (R2=65.19%, p=0.01). Dietary cholesterol intake was assessed, 
and explained 100% of the heterogeneity observed for HDL cholesterol 
(p<.0001). Cholesterol also explained significant heterogeneity for LDL 
(R2=35.05%, p=0.03). Dietary fiber intake explained between 13.50 and 43.23% 
of the heterogeneity observed for the four outcomes, but was only significant for 
change in HDL (R2TG =43.23%, p=0.09; R2TChol=13.50%, p=0.13; R2LDL =18.26%, 
p=0.10; R2HDL=15.64%, p=0.04). A table of the moderator analysis results for the 
low-fat diet without statins can be found in Table 8. 
Low-Fat Diet and Statins Moderator Analysis 
 All variables with adequate reporting of information from studies were 
evaluated to account for heterogeneity of low-fat diet studies as well. Longer 
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intervention length yielded significantly more beneficial effects, explaining 
19.22% for LDL and 23.64% for total cholesterol.  
 A predictive model was also used for the low-fat diet studies at the 
minimum and maximum lengths of intervention (3 and 104 weeks) to evaluate 
the magnitude of effect. Length of intervention was again found to be significant 
for both total cholesterol (B = -0.01, p=0.0037) and LDL (B = -0.01, p=0.003), 
showing that longer interventions with a low-fat diet with statin drugs produce 
greater reductions. Proportion of female was also significant for total and LDL 
cholesterol (R2TChol = 20.43%, p=0.0434; R2LDL = 14.76%, p=0.0180), with 
predictive models showing greater proportions of female subjects leading to 
greater decreases in total (B = 0.78, p=0.0434) and LDL (B = 1.05, p=0.0180) 
cholesterol.  
 Recommended macronutrient distributions and various recommendations 
on dietary intake were analyzed as moderators, and predictive models were used 
to analyze the proportions if found to be significant. Proportion of fat was 
significant for total cholesterol (R2TChol = 9.66%, p=0.0476), with the predictive 
model showing the greater proportion of fat intake leading to greater decreases 
in total cholesterol levels (B = 0.01, p=0.0476). Recommended proportion of 
carbohydrate intake was found to be a significant moderator for total cholesterol 
and LDL cholesterol, explaining 26.85% and 11.90% of the heterogeneity, 
respectively. For both outcomes, predictive models showed lower carbohydrate 
intake producing greater decreases (BTChol = 9.01, p=0.0026, BLDL = 7.26, 
p=0.0459). Recommended protein intake was analyzed, and only significant for 
HDL-cholesterol, accounting for 12.52% (p = 0.0476) of the variability observed 
among the studies. Lower protein intake yielded a greater improvement in HDL 
cholesterol levels, according to predictive models (B = -10.60, p=0.0408). Lastly, 
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recommended cholesterol intake was found to be significantly associated with 
change in HDL (R2HDL = 18.05%, p=0.0173). Minimum and maximum 
recommendations were used in the predictive model (31mg and 300mg per day), 
and showed greater increases in HDL cholesterol with greater cholesterol intake 
(B = -0.0017, p=0.0173). 
 Intervention characteristics, such as total sample size, intervention group 
size, number of intervention groups, level of supervision in the intervention, and 
provision of food items were analyzed. Total sample size explained significant 
heterogeneity for total cholesterol, LDL, and HDL (R2TChol = 26.51%, p=0.0008; 
R2LDL = 28.32%, p=0.0013, R2HDL = 31.07%, p=0.0013). Minimum and maximum 
sample sizes (19 and 3390) were used in predictive models, and showed greater 
decreases in total cholesterol and LDL cholesterol, and greater increases in HDL 
cholesterol with larger sample sizes (BTChol = 0.0003, p=0.0008, BLDL = 0.0003, 
p=0.0013, BHDL = 0.0001, p=0.0013).  Intervention group size significantly 
explained between 16.58 and 22.16% of the variation among studies for all four 
serum lipid outcomes, with larger intervention group sizes providing greater 
improvements. Number of intervention groups was a significant moderator for 
total cholesterol and HDL (R2TChol = 17.62%, p=0.0120; R2HDL = 35.03%, 
p<.0001). Level of intervention specifically having one-on-one intervention 
sessions with study participants, explained a small, but still significant amount of 
heterogeneity for HDL cholesterol (R2HDL = 3.34%, p=0.0078). Provision of food 
intake was analyzed, and only found to be significant for change in total 
cholesterol levels (R2TChol = 14.38%, p=0.0191). 
Different disease states were used as moderators if significant data were 
reported by the studies. Number of subjects with cardiovascular disease 
explained significant variation for total cholesterol, LDL, and HDL cholesterol 
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(R2TChol = 49.05%, p<.0001; R2LDL = 60.15%, p<.0001, R2HDL = 25.43%, 
p=0.0084). Use of predictive models showed greater improvements in these 
three serum lipid outcomes with more subjects carrying a diagnosis of 
cardiovascular disease. Dyslipidemia was not used as a moderator because all 
subjects in the low-fat diet studies who were on statins carried a diagnosis of 
dyslipidemia; therefore, the random-effects analysis already included the effects 
of a low-fat diet with statins on individuals with dyslipidemia.  
Additionally, changes in weight and funding source were assessed as 
moderators. Studies only reported enough data on weight maintenance to allow 
for analysis. Weight maintenance significantly explained 16.35% and 15.44% of 
variation among studies for LDL and HDL cholesterol 
Other variables analyzed included study region (United States and 
Europe), hypertension, current smokers, and statin dose. None of these variables 
were found to be significant. A summary of the low-fat diet with statins moderator 
analyses can be found in Table 9. All insignificant moderators tested for all three 
dietary interventions can be found in Table 10, and moderators unable to be 
analyzed due to lack of reported information in studies in Table 11. 
Risk of Bias 
For the Mediterranean diet studies, moderator analysis was not significant 
for any of the risk of bias parameter. There was a low risk of bias found for 58.3% 
of studies for random sequence generation, and 25.0% for allocation of control. 
For blinding of participants, low risk of bias was observed for 41.7% of studies, 
and high risk of bias for 8.3%. For incomplete outcome data for both short term 
and long term reporting, 33.3% of studies had a low risk, and 8.3% had high risk. 
There was no reported data on high or low risk of selective outcome reporting. 
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For other potential threats of validity, 16.7% of studies had high risk. Figure 31 
shows a summary for risk of bias reporting.  
For low-fat diet with statin studies, no parameter was significant for risk of 
bias when analyzed as a moderator. For random sequence generation, 90.9% of 
studies had low risk of bias, and 9.1% had high risk. 59.1% of studies had low 
risk of bias and 13.6% with high risk for allocation of control. For blinding of 
participants, 27.3% of studies had low risk of bias and 36.4% with high risk. 
There were no studies reporting high risk of bias for incomplete outcome data, 
and 54.5% had a low risk. Insufficient information was reported for selective 
outcome reporting to evaluate studies as low or high risk of bias. 18.2% of 
studies had low risk of bias for other potential bias, and 9.1% had a high risk. 
Figure 32 shows a summary for risk of bias reporting for the low-fat diet and 
statin studies. 
Discussion 
 This meta-analysis of 12 Mediterranean diet studies found the 
consumption of a Mediterranean diet yields significant decreases in triglycerides, 
total cholesterol, LDL-cholesterol, and HDL-cholesterol in adults who are at high-
risk and with existing CVD. The moderator analysis supported our primary 
hypothesis that statin drugs did not alter the relationship between the 
Mediterranean diet and serum lipids in adults, both at-risk and with existing CVD. 
The meta-analysis of 22 low-fat diet studies also reached significance: the low-fat 
diet alone significantly improved total cholesterol and LDL cholesterol, and there 
were even greater improvements observed in low-fat diet with statins 
interventions for all four serum lipid outcomes. When compared to the effects of a 
low-fat diet, the Mediterranean diet produced greater effect sizes for all four 
serum lipids; therefore the secondary hypothesis was accepted. Our third 
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hypothesis stated the Mediterranean diet would be equally effective in improving 
serum lipids compared to the traditionally prescribed low-fat diet and statin drug 
therapy combination. Results showed the low-fat diet with statins produced 
greater outcomes for total, LDL, and HDL cholesterol, resulting in rejecting out 
third hypothesis. 
 This meta-analysis provides new information for achieving improvements 
in serum lipids with dietary modification alone and with statin therapy. These 
results suggest a low-fat diet with statins remains the best recommendation for 
serum lipid lowering in adults at high-risk and with existing CVD; however, 
significant improvements observed with the Mediterranean and low-fat diets 
support the need for dietary modification in the prevention and treatment of CVD. 
 The moderator analysis explained significant sources of heterogeneity 
among the studies for the Mediterranean diet, low-fat diet, and low-fat diet with 
statin interventions. The Mediterranean diet was found to produce significantly 
better outcomes for triglycerides when the study was conducted in a European 
country. A possible explanation for this is greater access to food components of 
the Mediterranean diet when living in a Mediterranean country, as well as 
Mediterranean country culture placing a higher value on food and meal 
enjoyment than Western culture. Further, the low-fat diet alone showed to be 
more beneficial when conducted in the United States. During the mid-1990’s, 
low-fat diets increased significantly in popularity in America. Living in an 
environment that encourages the prescribed dietary pattern likely increases 
adherence, leading to better outcomes. 
 Longer interventions lead to greater improvements for total, LDL, and 
HDL cholesterols in the Mediterranean diet and low-fat diet with statins 
interventions, and for triglycerides in the low-fat diet without statin interventions. 
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This is consistent with observations in previous studies of greater and longer 
adherence to a Mediterranean diet17,84,85. Greater number of follow-up sessions, 
and subjects counseled in one-on-one or small group sessions led to greater 
improvements in triglycerides, and trend towards greater improvements for total 
and LDL cholesterol in the Mediterranean diet, with a possible explanation of 
subjects feeling a greater level of support with repeated contact.  
For low-fat diet with and without statins, greater proportion of female 
subjects had significant or trends towards greater improvements in total, LDL, 
and HDL cholesterol. This suggests that female subjects may benefit more from 
a low-fat diet. A 2014 meta-analysis by Wu, Ma, Walton-Moss, and He evaluated 
a low-fat diet on serum lipids in premenopausal and postmenopausal women. 
Their results found significant improvements in total, LDL, and HDL in 
premenopausal women, but further studies were needed to evaluate the effects 
in postmenopausal women. Therefore, these moderator results are consistent 
with observations in other studies86. 
Analyzing dietary recommendations provided greater insight to the effects 
of diet composition in outcomes. Higher recommendation for proportion of fat 
intake was found to yield greater improvements in total cholesterol, and higher 
intake of dietary cholesterol lead to greater improvements in HDL cholesterol 
levels in low-fat diet with statin interventions. This supports the 2015 Dietary 
Guidelines for Americans statement; “Cholesterol is not a nutrient of concern for 
overconsumption” 87. Higher protein intake was inversely associated with 
improvement in HDL cholesterol for both low-fat diet interventions. Mediterranean 
and low-fat diets tend to have similar recommendations of protein intake of 10-
20%. The literature shows conflicting evidence of the benefits of higher protein 
intake on cardiometabolic risk factors and overall health88,89. 
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  The mechanisms in which these interventions improve serum lipids differ 
and can greatly impact overall health. Beyond inhibiting the HMG-CoA reductase 
enzyme, statins decrease cholesterol ester transferase protein (CETP), a protein 
that promotes the transfer of cholesterol esters from HDL to more atherogenic 
cholesterols, such as IDL, VLDL, and LDL. This contributes to a rise in HDL and 
a decrease in LDL cholesterol90. The mechanism of the Mediterranean diet, 
however, has not been clearly defined. There have been associations found 
between increased satiety from the high fat and fiber content of the diet leading 
to weight loss, which is associated with improvement in serum lipids. Individual 
components of the diet, such as extra-virgin olive oil, the primary fat source of the 
diet, moderate alcohol consumption, and omega-3 intake have also been 
associated with improvement in serum lipids and reduced risk of type 2 
diabetes91-93. Both mechanisms have shown to be effective. 
 Use of statins can pose side effects that the Mediterranean diet does not, 
which can interfere with reaching cholesterol goals. For studies included in this 
analysis, statin dose levels ranged from 5 to 80mg, with those of higher doses 
(40 and 80mg) being of shorter duration. In the short duration of these studies of 
mostly 4 to 8 weeks, myalgia, rise in liver function tests, epigastric pain, and 
diarrhea were the most commonly reported side effects in studies that reported 
adverse effects. Though few subjects compared to the entire sample needed to 
withdraw treatment due to side effects, the short duration of these studies could 
have been motivation for subjects to continue treatment, despite adverse effects. 
A retrospective cohort study of Boston-area hospitals analyzed the rate of statin 
discontinuation and rate of adverse effects in 107,835 patients. The study found 
17.4% of patients experienced adverse effects, with myalgia being the most 
commonly reported reason. Of this group experiencing adverse effects, 59.1% of 
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them needed to at least temporarily discontinue statin therapy94. Conversely, the 
Mediterranean diet does not have side effects, and provides benefits beyond its 
lipid-lowering capabilities, including: weight loss, decreased inflammatory 
markers, decreased insulin resistance and risk for developing type 2 diabetes, 
decreased blood pressure, improvement in endothelial function, and slowed 
cognitive decline with aging49,95-98. Further, patients discontinue statin use for 
reasons other than adverse effects. Because of the symptomless nature of 
dyslipidemia, patients do not have the same motivation to adhere to their 
medication regimen that they would with a symptomatic disease. Other possible 
reasons for lack of adherence include lack of communication with physician, 
medication costs, and complex medication regimens. As a result, 50% or more 
patients discontinue statin use within one year after the start of treatment, with 
further decrease over time99. Diet, however, is a natural part of day-to-day life 
that can be modified with simple nutritional counseling by a registered dietitian.  
 Further investigation is warranted to provide an answer to which 
intervention is more beneficial to patients. This analysis provides a foundation for 
future studies to be conducted on the Mediterranean diet and statin drug therapy. 
Strengths and Limitations  
 There are many strengths to this study. These include a comprehensive 
coding form with over 330 variables was used to extract data from the studies. 
This coding for was thoroughly pilot tested for accuracy. Having many 
characteristics coded allows further investigation to explain heterogeneity among 
the studies.  We used predictive models to evaluate the effects of significant 
moderators at multiple levels. A comprehensive literature search was conducted 
with the help of a professional university librarian to ensure all relevant studies on 
the topic were included on the Mediterranean diet and low-fat diet with statins. 
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There are also limitations of this study. First, the literature search for low-fat diet 
studies was aimed at low-fat diet with statin drug interventions. The search likely 
missed studies with only a low-fat diet intervention due to adding in the analysis 
of low-fat diet alone to the Mediterranean diet after the search was conducted. 
Exclusion criteria did not address subjects with Liver Disease, another disease 
state that is associated with lipodystrophy. None of the included studies stated 
subjects with the condition, however they may not have addressed it in their 
exclusion criteria. This analysis did not take into account the characteristics, such 
as lipophilic versus hydrophilic, generation, or method of metabolism, of different 
types of statin drugs, which may have an effect on results. Further, we did not 
analysis changes in inflammatory markers, which have a large impact on the 
development and progression of cardiovascular disease. The low-fat diet studies 
also had a mean publication of ten years earlier than the Mediterranean diet 
studies. Due to the high societal presence of Familial Hypercholesterolemia, and 
the lack of studies identifying subjects carrying this mutation, we were unable to 
evaluate if the effects of the diet are more beneficial for those with genetically or 
lifestyle induced dyslipidemias. Uncontrolled or unaccounted level of exercise of 
the subjects may cause a change in lipid profile. Subjects of the Mediterranean 
diet trials may have been prescribed a statin regimen either before or during the 
intervention, but did not inform the principal investigator of their study, causing 
subjects to be missed for this analysis. As with all meta-analyses, we were 
limited to what studies reported, as the data used in this analysis was mostly 
published data. If raw data for all studies were provided for the analysis, it would 
allow for an Individual Participant Data (IPD) meta-analysis, which is the gold 
standard of meta-analyses. This would ensure greater accuracy of the results. 
Further, multiple variables did not have sufficient reported data among studies to 
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be analyzed, resulting in significant heterogeneity among the studies that could 
not be explained by the moderators analyzed. 
Clinical Implications 
 This preliminary work in the area of Mediterranean diet with statins 
suggests combined therapy of Mediterranean diet with statin drug therapy may 
be unwarranted. Further research is needed to understand the relationship 
between the Mediterranean diet with statins as a recommendation for prevention 
and treatment of CVD. In subjects desiring dietary modification without statin 
treatment, the Mediterranean diet showed to be more favorable than low-fat diet, 
which holds consistent with previous studies (Sofi, 2104; Garcia 2015; Kastorini 
2011). The low-fat diet with statin drugs provided greatest improvements in 
serum lipids, and therefore is very beneficial for subjects who require more 
aggressive lipid-lowering therapy96. 
Future Directions  
 This research supports the need for future trials to be conducted to further 
investigate the effects of Mediterranean diet in combination with statin drug 
therapy. The question still stands about the accuracy of the cholesterol 
hypothesis due to many trials finding substantially greater decreases in morbidity 
and mortality with consumption of a Mediterranean diet as opposed to a low-fat 
diet with statins.  Future analysis should evaluate the outcomes of cardiac death 
or cardiac events in individuals who adopt a Mediterranean diet with and without 
statin therapy, as well as to those on statin therapy with a low-fat diet to truly test 
the accuracy of the hypothesis. Future work can also examine the incidence of 
individuals who can lower their lipid levels with diet to a point of being able to 
lower dosage or discontinue use of statin drugs. A comparison of individuals with 
diet-induced hyperlipidemia versus Familial Hyperlipidemia using Mediterranean 
29 	
diet can be performed to assess if the diet with and without statin drugs has a 
significant effect on this extremely common genetic defect. This analysis can be 
the beginning of a more broad area of research comparing the Mediterranean 
diet to various types of drugs for other disease states, such as Type 2 Diabetes 
and hypoglycemic agents and Hypertension with antihypertensive medications. 
 
Conclusion 
 The results of this meta-analysis show the Mediterranean diet can 
successfully lower total cholesterol, LDL, and triglycerides, and raise HDL 
cholesterol, and statin drugs do not contribute to improvement in serum lipids 
when combined with the Mediterranean diet when assessed with moderator 
analysis. The Mediterranean diet produces greater improvements in all four 
serum lipids than a low-fat diet, and a low-fat diet with statin drugs produces the 
greatest improvements among the three interventions. This pilot work supports 
the need for the need for clinical trials need to directly evaluate the effects of the 
Mediterranean diet with and without statin drug therapy to provide evidence of it’s 
effects. This meta-analysis favors both the Mediterranean diet and low-fat diet 
with statin drugs as effective lipid-lowering interventions for adults at high-risk 
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Figure 3: Mediterranean Diet and Triglycerides Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 



















Figure 4: Mediterranean Diet and Total Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 



















Figure 5: Mediterranean Diet and LDL-Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 



















Figure 6: Mediterranean Diet and HDL-Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 



















Figure 7: Low-Fat Diet and Triglycerides Forest Plot
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 


















Figure 8: Low-Fat Diet and Total Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 













Figure 9: Low-Fat Diet and LDL-Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 













Figure 10: Low-Fat Diet and HDL-Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 



















Figure 11: Low-Fat Diet with Statins and Triglycerides Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 














Figure 12: Low-Fat Diet with Statins and Total Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 













Figure 13: Low-Fat Diet with Statins and LDL-Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 













Figure 14: Low-Fat Diet with Statins and HDL-Cholesterol Forest Plot 
 
Note: Squares represent point estimates for each individual study; extended line 
shows 95% confidence intervals (Cis); dotted line represents the null value of 













Figure 15: Mediterranean Diet and Length of Intervention 
 
Note: Number of weeks of the interventions is represented on the x-axis; Outcome of 
interest is represented on the y-axis; B is the unstandardized beta and represents the 
amount of change in the outcome per week of the intervention; R2 indicates the 
percentage of variability accounted for by length of intervention. 
 
 
Figure 16: Mediterranean Diet and Proportion of Subjects with Dyslipidemia  
 
Note: Proportion of subjects with a diagnosis of dyslipidemia is represented on the x-axis; 
Outcome of interest is represented on the y-axis; B is the unstandardized beta and 
represents the amount of change in the outcome per percent of subjects with 






Figure 17: Mediterranean Diet and Number of Follow-Up Sessions  
 
Note: Number of Follow-Up Session throughout the intervention is represented on the x-
axis; Outcome of interest is represented on the y-axis; B is the unstandardized beta and 
represents the amount of change in the outcome per follow-up; R2 indicates the 




Figure 18: Mediterranean Diet and Number of Subjects Lost to Follow-Up 
 
Note: Number of Subjects Lost to Follow-Up is represented on the x-axis; Outcome of 
interest is represented on the y-axis; B is the unstandardized beta and represents the 
amount of change in the outcome per lost subject; R2 indicates the percentage of 







Figure 19: Low-Fat Diet with Statins and Length of Intervention 
 
Note: Number of weeks of the interventions is represented on the x-axis; Outcome of 
interest is represented on the y-axis; B is the unstandardized beta and represents the 
amount of change in the outcome per week of the intervention; R2 indicates the 
percentage of variability accounted for by length of intervention. 
 
Figure 20: Low-Fat Diet with Statins and Length of Intervention 
 
Note: Number of weeks of the interventions is represented on the x-axis; Outcome of 
interest is represented on the y-axis; B is the unstandardized beta and represents the 
amount of change in the outcome per week of the intervention; R2 indicates the 





Figure 21: Low-Fat Diet with Statins and Proportion of Female Subjects 
 
Note: Proportion of females is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per percent increase in female subjects; R2 indicates the 
percentage of variability accounted for by proportion of females. 
 
 
Figure 22: Low-Fat Diet with Statins and Proportion of Female Subjects 
 
Note: Proportion of females is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per percent increase in female subjects; R2 indicates the 
percentage of variability accounted for by proportion of females. 
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Figure 23: Low-Fat Diet with Statins and Recommended Proportion of Fat Intake 
 
 
Note: Proportion of fat intake is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per percent increase in fat intake recommendation; R2 indicates 
the percentage of variability accounted for by proportion of fat intake. 
 
 
Figure 24: Low-Fat Diet with Statins and Recommended Proportion of 
Carbohydrate Intake 
 
Note: Proportion of carbohydrate intake is represented on the x-axis; Outcome of interest 
is represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per percent increase in carbohydrate intake recommendation; R2 
indicates the percentage of variability accounted for by proportion of carbohydrate intake. 
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Figure 25: Low-Fat Diet with Statins and Recommended Proportion of 
Carbohydrate Intake 
 
Note: Proportion of carbohydrate intake is represented on the x-axis; Outcome of interest 
is represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per percent increase in carbohydrate intake recommendation; R2 
indicates the percentage of variability accounted for by proportion of carbohydrate intake. 
 
 




Note: Proportion of protein intake is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per percent increase protein intake recommendation; R2 indicates 
the percentage of variability accounted for by proportion of protein intake. 
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Figure 27: Low-Fat Diet with Statins and Recommended Dietary Cholesterol 
Intake 
 
Note: Recommended dietary cholesterol intake is represented on the x-axis; Outcome of 
interest is represented on the y-axis; B is the unstandardized beta and represents the 
amount of change in the outcome per milligram change in cholesterol intake 
recommendation; R2 indicates the percentage of variability accounted for by 
recommended dietary cholesterol intake. 
 
 
Figure 28: Low-Fat Diet with Statins and Sample Size 
 
Note: Sample size is represented on the x-axis; Outcome of interest is represented on 
the y-axis; B is the unstandardized beta and represents the amount of change in the 
outcome per change in number of subjects; R2 indicates the percentage of variability 




Figure 29: Low-Fat Diet with Statins and Sample Size 
 
Note: Sample size is represented on the x-axis; Outcome of interest is represented on 
the y-axis; B is the unstandardized beta and represents the amount of change in the 
outcome per change in number of subjects; R2 indicates the percentage of variability 
accounted for by sample size. 
 
 
Figure 30: Low-Fat Diet with Statins and Sample Size 
 
Note: Sample size is represented on the x-axis; Outcome of interest is represented on 
the y-axis; B is the unstandardized beta and represents the amount of change in the 
outcome per change in number of subjects; R2 indicates the percentage of variability 







Figure 31: Low-Fat Diet with Statins and Intervention Group Size 
 
Note: Intervention group size is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per change in number of subjects; R2 indicates the percentage of 
variability accounted for by intervention group size. 
 
Figure 32: Low-Fat Diet with Statins and Intervention Group Size 
 
 
Note: Intervention group size is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per change in number of subjects; R2 indicates the percentage of 





Figure 33: Low-Fat Diet with Statins and Intervention Group Size 
 
Note: Intervention group size is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per change in number of subjects; R2 indicates the percentage of 
variability accounted for by intervention group size. 
 
 
Figure 34: Low-Fat Diet with Statins and Intervention Group Size 
 
Note: Intervention group size is represented on the x-axis; Outcome of interest is 
represented on the y-axis; B is the unstandardized beta and represents the amount of 
change in the outcome per change in number of subjects; R2 indicates the percentage of 





Figure 35: Low-Fat Diet with Statins and Subjects with Cardiovascular Disease 
 
Note: Number of subjects with cardiovascular disease is represented on the x-axis; 
Outcome of interest is represented on the y-axis; B is the unstandardized beta and 
represents the amount of change in the outcome per change in number of subjects with 
cardiovascular disease; R2 indicates the percentage of variability accounted for by 
number of subjects with cardiovascular disease. 
 
 
Figure 36: Low-Fat Diet with Statins and Subjects with Cardiovascular Disease 
 
Note: Number of subjects with cardiovascular disease is represented on the x-axis; 
Outcome of interest is represented on the y-axis; B is the unstandardized beta and 
represents the amount of change in the outcome per change in number of subjects with 
cardiovascular disease; R2 indicates the percentage of variability accounted for by 





Figure 37: Low-Fat Diet with Statins and Subjects with Cardiovascular Disease 
 
Note: Number of subjects with cardiovascular disease is represented on the x-axis; 
Outcome of interest is represented on the y-axis; B is the unstandardized beta and 
represents the amount of change in the outcome per change in number of subjects with 
cardiovascular disease; R2 indicates the percentage of variability accounted for by 
















































Table 1: Description of Included Mediterranean Diet Studies 
 
 
Note. N, number of participants at baseline; F, females; T2DM, Type 2 Diabetes 
Mellitus; NR, not reported; MDN, Mediterranean diet with nuts supplemented; 
MDO, Mediterranean diet with olive oil supplemented; LFd, low fat;  MetS, 
Metabolic Syndrome; CVDRF, Cardiovascular Disease risk factors; inflam bio, 
inflammatory biomarkers; IDDM, Insulin Dependent Diabetes Mellitus; OverWT, 
Overweight; Ob, Obese;  IR, Insulin Resistance; NIDDM, Non-insulin Dependent 
Diabetes Mellitus; Chol, cholesterol; TG, Triglycerides; BG, Blood Glucose; CAD, 
Coronary Artery Disease;  Lp(a), lipoprotein-a;  MI, Myocardial Infarction; HTN, 
Hypertension; NCEP, National Cholesterol Education Program diet; CD, cardiac 
death; HypoMD, hypocaloric Mediterranean diet; CHO, carbohydrate; HypoLFD, 
hypocaloric low-fat. 
 




(weeks) Control Outcome 
Babio, et al 








MDN, MDO 250 LFD MetS 
Casas, et al 












Casas, et al 








MDN, MDO 260 LFD IDDM, CVDRF 
Esposito, et 










low CHO 208 HypoLFD 
IDDM, 
CVDRF 
Estruch, et al 




























Jula, et al 





































MDO, MDN 52 LFD MetS, MS RF 
Simoni, et al 
(1994)110 Italy 12 42% 70 
High serum 
lipids, Lp(a) 
Subsample of an 




Singh, et al 








Tuttle, et al 
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Table 2: Description of Included Low-Fat Diet Studies 
 







Andrews, et al 
(1997)113 




AHA Step 1 
Statin 
24 AHA Step 1 Serum 
lipids, 
ischemia  
Aquilani, et al 
(1998)114 
























24 AHA Step  
1 Placebo,  









56 14% 51 HLD Study Centers Individual, 
Unsupervised 
AHA Step 1 
Statin 




Bradford, et al 
(1993)117 




Unsupervised AHA Step 1 
Statin 




Brown, et al 
(1998)118 










54 None Serum 
lipids 




19 58% 51 FH, HLD  Lipid Clinic  Individual & 
Group, 
Unsupervised 
LFD Statin 32 HFD Statin Serum 
lipids 
Clifton, et al 
(1991)120 










Coban, et al 
(2007)121 










Cobb, et al 
(1991)83 
















LFD 12 None Serum 
lipids, BG 
Galvan, et al 
(1996)123 









Hodis, et al 
(1996)124 
USA 188 8% 58 HTN, CAD, 
50% 
stenosis 










et al (1993)125 












Jenkins, et al 
(2003)126 















Note. N, number of participants at baseline; F, females; CAD, Coronary Artery 
Disease; High Chol, High Total and LDL Cholesterol; HLD, Hyperlipidemia; DM, 
Diabetes Mellitus; NR, not reported; AHA step 1 or 2, American Heart 
Association Step 1 or Step 2 Diet; Chol, Cholesterol; VLFD, Very Low-Fat Diet; 
TG, Triglycerides; HTN, Hypertension; ASCVD, Atherosclerotic Cardiovascular 
Disease; FH, Familial Hypercholesterolemia; LFD, Low-fat diet; HFD, High-fat 
diet; MPV, Mean Platelet Volume; DYS, dyslipidemia; BG, Blood Glucose;  IR, 
Insulin Resistance; LCD, Low Cholesterol Diet, CAIMT, Carotid Arterial Intima-
Media Thickness; Outpt, Outpatient; PS, Plant Sterols; WG, Whole Grains; CRP, 
C-Reactive Protein; CHD Risk, Coronary Heart Disease Risk Percentage; ICAM-
1, Intracellular adhesion molecule- type 1; MDA, malondialdehyde; MOD, 
Minimum Obstruction Diameter; MSD, Mean Segment Diameter; inflam, 
inflammation. 
 
Note on Dietary Assessment column:  
• Individual: A dietitian performed a dietary assessment, providing 
individualized needs for caloric intake and recommendations, for each 
participant. 
• Group: The study provided general dietary recommendations for the 
participants, such as a range of servings of certain food groups, calories 
based on gender, as opposed to tailoring diets to individual needs based 
on weight and height. 
• Supervised: Participants consumed foods in a supervised setting, where 
the researchers had control over participant food choices and quantity of 
food served. 
• Unsupervised: Participants food consumption was unsupervised by 
researchers, such as eating at home. 









AHA Step 2 
Statin 
14 AHA Step 2 Serum 
lipids, 
inflam bio 











AHA Step 1 
Statin 






Mizuno, et al 
(2004)129 










Ose, et al 
(2000)130 
USA 1105 42% 52.8 HLD NR Individual, 
Unsupervised 
AHA Step 1 
Statin 
48 None Serum 
lipids 
Ose, et al 
(1995)131 




  Schafer, et al      
( (2001)132 







10 None Serum 
lipids 
 
Ziegler, et al 
(1990)133 France 184 30% 46 HLD NR Individual, Unsupervised LFD 10 None Serum lipids 
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Table 3: Mediterranean Diet Publication Bias Results 
Outcome Egger’s Begg’s 
Triglycerides p=0.73 p=0.16 
Total Cholesterol p=0.90 p=1.000 
LDL p=0.61 p=0.12 
HDL p=0.45 p=0.44 
 
Table 4: Low Fat Diet Publication Bias Results 
Outcome Egger’s Begg’s 
Low-Fat Diet without Statins 
Triglycerides p=0.47 p=0.82 
Total Cholesterol p=0.01 p=0.60 
LDL p=0.01 p=0.44 
HDL p=0.36 p=0.21 
Low-Fat Diet with Statins 
Triglycerides p=0.39 p=0.06 
Total Cholesterol p=0.07 p=0.75 
LDL p=0.23 p=0.12 
HDL p=0.101 p=0.80 
 
Table 5: Mediterranean Diet Summary of Results 
Outcome K Fixed-Effects Random-Effects Q I2 P-value 











73.24 91.84% <.0001 




147.39 93.25% <.0001 




116.74 93.53% .04 
 
Table 6: Low-Fat Diet Summary of Results 
Low-Fat Diet Without Statins 
Outcome K Fixed-Effects Random-Effects Q I2 P-value 











183.94 91.12% <.0001 




70.92 79.50% 0.0002 




140.08 95.01% 0.62 
Low-Fat Diet With Statins 











600.61 95.59% <.0001 




723.97 96.75% <.0001 




299.10 84.32% <.0001 
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Table 7: Mediterranean Diet Significant Moderator Analysis Results 
Variable Outcome Category K d+(95%CI) R2 p-value 
Statins TG 0% 13 -0.39 
(-1.00, 0.22) 
0.00% 0.80 
  7% (min) 13 -0.40 
(-0.95, 0.15) 
0.00% 0.80 
  10% 13 -0.40  
(-0.93, 0.12) 
0.00% 0.80 
  25% 13 -0.43 
(-0.84, -0.01) 
0.00% 0.80 
  50% 13 -0.46 
(-0.82, -0.10) 
0.00% 0.80 
  75% 13 -0.50 
(-0.99, -0.01) 
0.00% 0.80 







0% 10 -0.65  
(-1.17, -0.14) 
0.00% 0.96 
  7% (min) 10 -0.65  
(-1.12, -0.19) 
0.00% 0.96 
  10% 10 -0.66 
(-1.10, -0.21) 
0.00% 0.96 
  25% 10 -0.66  
(-1.02, -0.30) 
0.00% 0.96 
  50% 10 -0.66 
(-1.02, -0.32) 
0.00% 0.96 
  75% 10 -0.67  
(-1.16, -0.18) 
0.00% 0.96 
  100% 10 -0.68 
(-1.37, 0.02) 
0.00% 0.96 
 LDL 0% 12 -0.38  
(-0.86, 0.10) 
0.00% 0.47 
  7% (min) 12 -0.40 
(-0.83, 0.02) 
0.00% 0.47 
  10% 12 -0.41 
(-0.82, -0.01) 
0.00% 0.47 
  25% 12 -0.46  
(-0.78, -0.14) 
0.00% 0.47 
  50% 12 -0.54 
(-0.81, -0.27) 
0.00% 0.47 
  75% 12 -0.62 
(-1.00, -0.25) 
0.00% 0.47 
  100% 
(max) 
12 -0.70  
(-1.25, -0.15) 
0.00% 0.47 
 HDL 0% 13 0.39 
(0.01, 0.78) 
2.08% 0.32 
  7% (min) 13 0.37 
(-0.02, 0.72) 
2.08% 0.32 
  10% 13 0.36 
(0.03, 0.69) 
2.08% 0.32 
  25% 13 0.30 
(0.04, 0.57) 
2.08% 0.32 
  50% 13 0.21 
(-0.1, 0.44) 
2.08% 0.32 









Dyslipidemia TG 15% (min) 10 0.75 
(-0.26, 1.75) 
14.36% 0.15 







15% (min) 8 -0.95  
(-1.49, -0.42) 
1.40% 0.53 
  100% 
(max) 
8 -0.68  
(-1.13, -0.22) 
1.40% 0.53 
 LDL  15% (min) 9 0.45 
(-0.71, 1.61) 
11.07% 0.06 





 HDL 15% (min) 10 0.94 
(0.61, 1.27) 
81.20% <0.0001 



















Yes 10 -1.15 
(-2.01, -0.29) 
0.00% 0.23 
  No 10 -0.58 
(-0.93, -0.23) 
0.00% 0.23 
 LDL Yes 12 -1.26 
(-1.97, -0.55) 
14.03% 0.03 
  No 12 -0.43 
(-0.67, -0.18) 
14.03% 0.03 
 HDL Yes 13 -0.01 
(-0.64, 0.61) 
0.35% 0.40 





TG Yes 13 -0.57 
(-1.54, 0.41) 
0.00% 0.87 





Yes 9 -0.65  
(-1.29, -0.01) 
0.00% 0.83 
  No 9 -0.58 
(-0.91, -0.24) 
0.00% 0.83 
 LDL Yes 10 0.00 
(-0.78, 0.78) 
2.19% 0.24 
  No 10 -0.47 
(-0.71, -0.23) 
2.19% 0.24 
 HDL Yes 11 0.78 
(0.30, 1.26) 
35.78% 0.02 




Using Insulin  
TG Yes 8 -0.99 
(-1.23, -0.75) 
98.32% <0.0001 






Yes 6 -1.24 
(-1.99, -0.49) 
31.11% 0.10 
  No 6 -0.54 
(-0.89, -0.19) 
31.11% 0.10 



























  Maximum 
(260) 
8 -1.04  
(-1.45, -0.64) 
54.74% 0.02 






















TG 1-on-1 13 -0.26 
(-0.58, 0.06) 
32.00% 0.02 







1-on-1 10 -0.74 
(-1.10, -0.38) 
0.00% 0.37 





 LDL 1-on-1 12 -0.54 
(-0.85, -0.23) 
0.00% 0.86 



























  Maximum 
(8) 
10 -1.02  
(-1.67, -0.36) 
12.75% 0.23 





























































  Maximum 
(14) 
10   -1.28 
(-2.15, -0.40) 
16.14% 0.14 



























 8 -1.52 
(-2.28, -0.76) 
42.96% 0.01 
 LDL  10 -0.63 
(-1.43, 0.18) 
0.00% 0.65 
 HDL  11 0.84 
(0.49, 1.19) 
61.22% <0.0001 
 HDL Yes 8 1.12 
(0.71, 1.52) 
78.57% <0.0001 
  No 8 0.19 
(0.04, 0.35) 
78.57% <0.0001 
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Table 8: Low-Fat Diet Significant Moderator Analysis Results 
Variable Outcome Category K d+(95%CI) R2 p-value 















































































































































 Total Minimum 16 -0.92 0.00% 0.33 
67 	
Cholesterol (0) (-2.10, 0.26) 
















































































































































  Maximum 11 -0.18 0.00% 0.61 
68 	
(54%) (-0.59, 0.23) 






























































































































  Maximum 
(5850) 
17 0.35 
(-0.22, 0.93)  
32.80% 0.04 


























  Europe 17 -0.29 
(-0.54, -0.04) 
0.00% 0.45 





  Europe 17 -0.24 
(-0.42, -0.07) 
0.00% 0.38 





  Europe 19 -0.03 
(-0.34, 0.27) 
0.00% 0.73 
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Table 9: Low-Fat Diet with Statins Significant Moderator Analysis Results 
Variable Outcome Category K d+(95%CI) R2 p-value 
Proportion of 
Females 
TG 0% (min) 27 -0.44 
(-0.71, -0.16) 
0.00% 0.98 







0% (min) 37 -1.35 
(-1.73, -0.96) 
10.43% 0.04 





 LDL 0% (min) 36 -1.31 
(-1.75, -0.18) 
14.76% 0.02 





 HDL 0% (min) 37 0.27 
(0.13, 0.41) 
16.62% 0.08 









TG 5 (min) 12 -0.34 
(-0.80, 0.11) 
0.00% 0.60 





5 (min) 21 -0.99 
(-1.40, -0.59) 
49.05% <.0001 
  113 (max) 21 -2.55 
(-3.02, -2.08) 
49.05% <.0001 
 LDL 5 (min) 21 -0.96 
(-1.33, -0.60) 
60.15% <.0001 





HDL 5 (min) 21 0.22 
(0.05, 0.38) 
25.43% 0.008 





TG 3 (min) 27 -0.45 
(-0.65, -0.26) 
0.00% 0.77 





3 (min) 37 -1.39 
(-1.67, -1.11) 
19.22% 0.004 
  208 (max) 37 -3.71 
(-5.09, -2.33) 
19.22% 0.004 
 LDL 3 (min) 36 -1.40 
(-1.73, -1.08) 
23.64% 0.003 
  208 (max) 36 -4.10 
(-5.67, -2.53) 
23.64% 0.003 
 HDL 3 (min) 37 0.29 
(0.18, 0.41) 
8.93% 0.06 





TG 19 (min) 27 -0.34 
(-0.49, -0.19) 
16.73% 0.04 








19 (min) 37 -1.46 
(-1.71, -1.22) 
22.16% 0.003 





 LDL 19 (min) 36 -1.52 
(-1.81, -1.23) 
19.23% 0.009 





 HDL 19 (min) 36 0.30 
(0.20, 0.39) 
16.58% 0.02 








TG 1 (min) 27 -0.46 
(-0.74, -0.18) 
0.00% 0.81 





1 (min) 37 -1.17 
(1.62, -0.72) 
17.62% 0.01 
  5 (max) 37 -2.07 
(-2.43, -1.71) 
17.62% 0.01 
 LDL 1 (min) 36 -1.29 
(-1.83, -0.75) 
12.26% 0.06 
  5 (max) 36 -2.09 
(-2.52, -1.66) 
12.26% 0.06 
 HDL 1 (min) 36 0.12 
(-0.03, 0.27) 
35.03% <.0001 
  5 (max) 36 0.57 
(0.45, 0.68) 
35.03% <.0001 





































TG 17% (min) 27 -0.36 
(-0.64, -0.09) 
0.00% 0.56 





17% (min) 37 -1.43 
(-1.94, -0.93) 
9.66% 0.048 
  30% (max) 37 -1.72 
(-1.96, -1.49) 
9.66% 0.048 




  30% (max) 36 -1.70 
(-1.97, -1.42) 
0.00% 0.25 
 HDL 17% (min) 37 0.27 
(0.07, 0.47) 
2.47% 0.26 






















  67% (max) 28 -0.64 
(-1.37, 0.10) 
26.85% 0.003 





  67% (max) 27 -0.83 
(-1.72, 0.06) 
11.90% 0.046 











TG 15% (min) 18 -0.53 
(-0.73, -0.32) 
0.00% 0.35 





15% (min) 28 -1.76 
(-2.01, -1.51) 
1.84% 0.30 
  21% (max) 28 -1.23 
(-2.16, -0.30) 
1.84% 0.30 
 LDL 15% (min) 27 -1.74 
(-2.02, -1.45) 
0.60% 0.42 
  21% (max) 27 -1.13 
(-2.55, 0.29) 
0.60% 0.42 
 HDL 15% (min) 27 0.43 
(0.33, 0.52) 
12.52% 0.04 






TG 31 (min) 20 -0.13 
(-0.58, 0.33) 
7.30% 0.10 





31 (min) 30 -1.17 
(-1.90, -0.45) 
6.94% 0.11 
  300(max) 30 -1.85 
(-2.12, -1.58) 
6.94% 0.11 
 LDL 31 (min) 29 -1.16 
(-2.03, -0.29) 
4.62% 0.19 
  300(max) 29 -1.82 
(-2.12, -1.52) 
4.62% 0.19 






























TG Yes 27 -0.36 
(-0.66, -0.07) 
0.00% 0.60 





Yes 37 -1.82 
(-2.42, -1.22) 
0.00% 0.62 
  No 37 -0.16 
(-0.81, -1.42) 
0.00% 0.62 
 LDL Yes 36 -2.39 
(-3.08, -1.70) 
5.39% 0.049 
  No 36 -1.65 
(-1.92, -1.34) 
5.39% 0.049 
 HDL Yes 36 0.34 
(0.13, 0.55) 
0.00% 0.76 





TG Yes 27 -0.46 
(-0.60, -0.32) 
2.93% 0.19 





Yes 37 -1.75 
(-1.96, -1.54) 
14.38% 0.02 
  No 37 -0.81 
(-1.57, -0.05) 
14.38% 0.02 
 LDL Yes 36 -1.82 
(-2.07, -1.56) 
9.88% 0.06 










Table 10: Non-Significant Moderators 
 
Mediterranean Diet Low-Fat Diet Low-Fat Diet with 
Statins 





Subjects recruited by a 
hospital 
Subject ethnicity 
Mean subject age 
Proportion with 
hypertension 
Proportion with Diabetes 
Mellitus 
Proportion taking ACE 
inhibitors 
Number taking ACE 
inhibitors 
Proportion taking statins 
Proportion of females 
Proportion of current 
smokers 
Provision of food 
Reported macronutrient 
distribution 




Number of intervention 
groups 
Type of control group 
Length of weeks between 
follow-ups 





Private Party Funding 
Intervention Group Size 
Current Smokers 
Proportion of Subjects 
with Cardiovascular 
Disease 
Proportion of Subjects 
with Type II Diabetes 
Mellitus 
Number of Subjects with 
Type II Diabetes Mellitus 
Number of Subjects with 
Dyslipidemia 
Proportion of Subjects 
Using Diuretics 
Number of Subjects 
Using Diuretics 
Subjects Taking Aspirin 
Supervision Level – One-
on-One 
Supervision Level – 
Small Group 
Weight Loss 
Number of Follow-Ups 
Length (in Weeks) 
Between Follow-Ups 




Number of Subjects Lost 
to Follow-Up 
Recommended 
Saturated Fat Intake 












Proportion of current 
smokers 
Statin dose (mg) 
Recommended sodium 
intake 
Length of weeks between 
follow-up 
Number of follow-up 
sessions 











Table 11: Moderators Unable to Analyze Due to Lack of Reported Information 
 




Proportion with Metabolic 
Syndrome 
Use of beta-blockers 
Use of nitrates 
Use of diuretics 
Use of NSAIDs 























Private funding source 
Subject Ethnicity 






Proportion with Metabolic 
Syndrome 






Proportion Using Nitrates 
Number Using Nitrates 
Proportion Using Calcium 
Channel Blockers 
Number Using Calcium 
Channel Blockers 







Unsaturated Fat Intake 
Recommended Sodium 
Intake 
Servings of Vegetables 
Servings of Dairy 
Servings of Wine 
Servings of Grains 
Servings of Fish 
Servings of Oil 
Servings of Nuts 
Servings of Legumes 
Servings of Meat 
Servings of Poultry 
Quality of Life 
Proportion with Diabetes 
Mellitus 
Proportion with Metabolic 
Syndrome 
Use of ACE inhibitors 
Use of beta-blockers 
Use of nitrates 
Use of diuretics 
Use of fibrates 
Use of calcium channel 
blockers 
Adherence to dietary 
intervention 
Weight loss 
Provision of food 
Recommended dietary 




















Appendix 1: Comprehensive Literature Search: Mediterranean Diet  
 
PubMed (1940s to present)  
Terms were searched in all fields; however, field labels were used to 
restrict specific terms/phrases to the Medical Subject Headings [Mesh], 
publication type [pt] and journal name [ta] fields.  
("Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" OR "Diet, 
Mediterranean"[Mesh])  AND (“Antihyperlipidemic medication” 
OR  “Antihyperlipidemic medications” OR statin OR statins OR  “HMG-CoA 
Reductase” OR  “cholesterol lowering agents” OR  “lipid lowering agents” 
OR  “HMG-CoA” OR  “bile acid sequestrants” OR  “resins” OR  “nicotinic acid” 
OR niacin OR  “fibric acid derivatives” OR  “fibrates” OR  “cholesterol absorption 
inhibitors” OR  “hydroxymethylglutaryl-CoA” OR "hydroxymethylglutaryl-coa 
reductase inhibitors"[Pharmacological Action] OR "hydroxymethylglutaryl-coa 
reductase inhibitors"[MeSH Terms] OR ("hydroxymethylglutaryl-coa"[All Fields] 
AND "reductase"[All Fields] AND "inhibitors"[All Fields]) OR statin* OR "HMG-
CoA Reductase"[All Fields] OR "HMG-CoA"[All Fields] OR 
"hydroxymethylglutaryl-CoA"[All Fields] OR "atorvastatin" OR 
"simvastatin"[MeSH Terms] OR "simvastatin" OR "rosuvastatin" OR 
"pravastatin"[MeSH Terms] OR "pravastatin" OR "lovastatin"[MeSH Terms] OR 
"lovastatin" OR "pitavastatin"[Supplementary Concept] OR "pitavastatin" OR 
"fluvastatin"[Supplementary Concept] OR "fluvastatin" OR 
"cerivastatin"[Supplementary Concept] OR "cerivastatin" OR 
"mevastatin"[Supplementary Concept] OR "mevastatin" OR "cardiovascular 
disease" OR "Cardiovascular Diseases"[Mesh] OR "cardiovascular diseases" OR 
"heart disease" OR "heart diseases" OR CVD OR CVDs OR 
"Hypertension"[Mesh] OR hypertension OR hypertensive* OR "high blood 
pressure" OR "Myocardial Infarction"[Mesh] OR "myocardial infarction" OR 
"myocardial infarct" OR "MI" OR "heart attack" OR "Stroke"[Mesh] OR stroke OR 
"Coronary Artery Disease"[Mesh] OR "coronary artery disease" OR "coronary 
arterial disease" OR "coronary heart disease" OR "Cerebrovascular 
Disorders"[Mesh] OR "Cerebrovascular Disorders" OR "cerebrovascular disease" 
OR "cerebrovascular diseases" OR "Atherosclerosis"[Mesh] OR atherosclerosis 
OR "Arteriosclerosis"[Mesh] OR arteriosclerosis OR "Peripheral Vascular 
Diseases"[Mesh] OR "peripheral vascular diseases" OR  "peripheral vascular 
disease" OR "peripheral angiopathy" OR "peripheral angiopathies" OR 
"Peripheral Arterial Disease"[Mesh] OR "peripheral arterial disease" OR 
"peripheral arterial diseases" OR "peripheral artery disease" OR "peripheral 
artery diseases" OR "Venous Thrombosis"[Mesh] OR "venous thrombosis" 
OR  "venous thromboses" OR "deep vein thrombosis" OR "deep 
vein thromboses" OR "Pulmonary Embolism"[Mesh] OR "pulmonary embolism" 
OR "pulmonary embolisms" OR "Dyslipidemias"[Mesh] OR dyslipidemia OR 
dyslipidemias OR "Hypercholesterolemia"[Mesh] OR hypercholesterolemia 
OR hypercholesterolemias OR "Aortic Valve Stenosis"[Mesh] OR "Aortic Valve 
Stenosis" OR "aortic stenosis" OR "aortic stenoses" OR "Aneurysm"[Mesh] OR 
Aneurysm OR aneurysms OR Aneurism OR regurgitation OR prolapse) AND 
(("clinical"[tiab] AND "trial"[tiab]) OR "clinical trials as topic"[mesh] OR "clinical 
trial"[pt] OR random*[tiab] OR "random allocation"[mesh] OR "therapeutic 
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use"[sh]) NOT ("Case Reports"[pt] OR Comment[pt] OR Editorial[pt] OR Letter[pt] 
OR "case control"[ti] OR "case report"[ti] OR "case study"[ti] OR "case series"[ti] 
OR "Case-Control Studies"[Mesh] OR "Follow-Up Studies"[Mesh] OR 
"observational study"[ti] OR "prospective cohort"[ti] OR "cohort studies" 
[Mesh:NoExp] OR "cohort study"[ti] OR "Follow-Up Studies"[mesh] OR 
"Retrospective Studies"[mesh] OR "non-randomized"[ti] OR "follow up study"[ti] 
OR rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti] 
OR (animals[MH] NOT humans[MH]))  
Results: 607  
  
EMBASE (via Scopus) (1823 to present)  
Limits: Article, review, conference papers, journals  
All terms (unless otherwise noted) were searched in "Article Title, 
Abstract, Keywords". Because of character restrictions in Scopus, this 
search was run in parts and assembled using the "Search history".  
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean 
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"  
AND  
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR 
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart 
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart 
disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein 
thrombosis" OR "pulmonary 
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"  
AND  
Option 1: (clinical AND trial)  
OR   
Option 2: "Clinical Trials" OR "clinical trial" OR random* OR "therapeutic use"  
AND NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"  
Results: 343  
  
  
CINAHL (1981-present)  
All terms were searched in all fields (unless otherwise noted)  
Excluded: MEDLINE Records  
Limited: Research Article  
Due to database limitations, search was run in parts and assembled using 
the search history.  
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean 
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"  
AND  
(“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR statin 
OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering agents” 
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OR  “lipid lowering agents” OR  “HMG-CoA” OR  “bile acid sequestrants” 
OR  “resins” OR  “nicotinic acid” OR niacin OR  “fibric acid derivatives” 
OR  “fibrates” OR  “cholesterol absorption inhibitors” OR  “hydroxymethylglutaryl-
CoA” OR statin* OR "atorvastatin" OR "simvastatin" OR "simvastatin" OR 
"rosuvastatin" OR "pravastatin” OR "lovastatin" OR "pitavastatin" OR 
"fluvastatin" OR "cerivastatin" OR "mevastatin" OR "cardiovascular 
disease" OR "cardiovascular diseases" OR "heart disease" OR "heart 
diseases" OR CVD OR CVDs OR hypertension OR hypertensive* OR "high 
blood pressure" OR "myocardial infarction" OR "myocardial 
infarct" OR "MI" OR "heart attack" OR stroke OR "coronary artery 
disease" OR "coronary arterial disease" OR "coronary heart disease" OR 
"Cerebrovascular Disorders" OR "cerebrovascular disease" OR "cerebrovascular 
diseases" OR atherosclerosis OR arteriosclerosis OR "peripheral vascular 
diseases" OR  "peripheral vascular disease" OR 
"peripheral angiopathy" OR "peripheral angiopathies" OR "peripheral arterial 
disease" OR "peripheral arterial diseases" OR "peripheral artery 
disease" OR "peripheral artery diseases" OR "venous thrombosis" 
OR  "venous thromboses" OR "deep vein thrombosis" OR "deep 
vein thromboses" OR "Pulmonary Embolism" OR "pulmonary embolisms" OR 
dyslipidemia OR dyslipidemias OR hypercholesterolemia 
OR hypercholesterolemias OR "Aortic Valve Stenosis" OR "aortic 
stenosis" OR "aortic stenoses" OR Aneurysm OR aneurysms OR Aneurism OR 
regurgitation OR prolapse)  
  
AND  
Option 1: (clinical AND trial)  
OR   
Option 2: (MH "Clinical Trials+") OR "clinical trial" OR random* OR (MH "Random 
Assignment") OR "therapeutic use"  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"  
 Results :  9  
  
PsycINFO  (1872 to present)  
Limits: academic journals  
Due to database limitations, search was run in parts and assembled using 
the search history.  
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean 
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"  
AND  
"cardiovascular disease" OR "cardiovascular diseases" OR "heart 
disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart 
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart 
disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein 
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thrombosis" OR "pulmonary 
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"  
AND  
Option 1: (clinical AND trial)  
OR   
Option 2: (DE "Clinical Trials") OR "clinical trial" OR random* OR (DE "Random 
Sampling") OR "therapeutic use"  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"  
 Results: 14  
  
Academic Search Premier (1980s to present)  
Limit:  Scholarly (Peer Reviewed) Journals  
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean 
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"  
AND  
"cardiovascular disease" OR "cardiovascular diseases" OR "heart 
disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart 
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart 
disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein 
thrombosis" OR "pulmonary 
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"  
AND  
Option 1: (clinical AND trial)  
OR   
Option 2: (random* OR "therapeutic use")  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"  
Results: 208  
  
Agricola (1970-present)  
Searched in "All Fields"   
Limits: academic journals  
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean 
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"  
AND  
"cardiovascular disease" OR "cardiovascular diseases" OR "heart 
disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
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pressure" OR "myocardial infarction" OR "MI" OR "heart 
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart 
disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein 
thrombosis" OR "pulmonary 
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"  
AND  
Option 1: (clinical AND trial)  
OR   
Option 2: (random* OR "therapeutic use")  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"  
Results: 40  
  
CAB Direct (1973-present)  
Limit to Document Type: Journal article and Evidence based research 
articles only  
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean 
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"  
AND  
"cardiovascular disease" OR "cardiovascular diseases" OR "heart 
disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart 
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart 
disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein 
thrombosis" OR "pulmonary 
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"  
AND  
Option 1: (clinical AND trial)  
OR   
Option 2: (random* OR "therapeutic use")  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"  
  
Results: 0 results  
  




Appendix 2: Comprehensive Literature Search: Low-Fat Diet 
 
PubMed (1940s to present)  
Terms were searched in all fields; however, field labels were used to 
restrict specific terms/phrases to the Medical Subject Headings [Mesh], 
publication type [pt] and journal name [ta] fields.   
(diet[majr] OR diet[ti] OR diets[ti] OR dietary[ti] OR “Dietary Fats” [majr] OR “low 
fat”[ti] OR “reduced fat”[ti] OR (“American Heart Association”[tiab] AND 
diet) OR (“Therapeutic lifestyle change” AND diet) OR (“therapeutic lifestyle 
changes” AND diet) OR  “DASH” OR “Dietary Approaches to Stop 
Hypertension” OR (“National Cholesterol Education Program” AND diet) OR “fat 
restricted”[ti] OR “lower fat”[ti] OR “hypolipidemic”[ti]) 
AND (“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR 
statin OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering agents” 
OR  “lipid lowering agents” OR  “HMG-CoA” OR  “bile acid sequestrants” 
OR  “resins” OR  “fibric acid derivatives” OR  “fibrates” OR  “cholesterol 
absorption inhibitors” OR  “hydroxymethylglutaryl-CoA” OR 
"hydroxymethylglutaryl-coa reductase inhibitors"[Pharmacological Action] OR 
"hydroxymethylglutaryl-coa reductase inhibitors"[MeSH Terms] OR 
("hydroxymethylglutaryl-coa"[All Fields] AND "reductase"[All Fields] AND 
"inhibitors"[All Fields]) OR statin* OR "HMG-CoA Reductase"[All Fields] OR 
"HMG-CoA"[All Fields] OR "hydroxymethylglutaryl-CoA"[All Fields] OR 
"atorvastatin" OR "simvastatin"[MeSH Terms] OR "simvastatin" OR 
"rosuvastatin" OR "pravastatin"[MeSH Terms] OR "pravastatin" OR 
"lovastatin"[MeSH Terms] OR "lovastatin" OR "pitavastatin"[Supplementary 
Concept] OR "pitavastatin" OR "fluvastatin"[Supplementary Concept] OR 
"fluvastatin" OR "cerivastatin"[Supplementary Concept] OR "cerivastatin" OR 
"mevastatin"[Supplementary Concept] OR "mevastatin” OR pravachol OR Zocor 
OR Lipitor) AND ("cardiovascular disease" OR "Cardiovascular Diseases"[Mesh] 
OR "cardiovascular diseases" OR "heart disease" OR "heart diseases" OR CVD 
OR CVDs OR "Hypertension"[Mesh] OR hypertension OR hypertensive* OR 
"high blood pressure" OR "Myocardial Infarction"[Mesh] OR "myocardial 
infarction" OR "myocardial infarct" OR "MI" OR "heart attack" OR "Stroke"[Mesh] 
OR stroke OR "Coronary Artery Disease"[Mesh] OR "coronary artery disease" 
OR "coronary arterial disease" OR "coronary heart disease" OR 
"Cerebrovascular Disorders"[Mesh] OR "Cerebrovascular Disorders" OR 
"cerebrovascular disease" OR "cerebrovascular diseases" OR 
"Atherosclerosis"[Mesh] OR atherosclerosis OR "Arteriosclerosis"[Mesh] OR 
arteriosclerosis OR "Peripheral Vascular Diseases"[Mesh] OR "peripheral 
vascular diseases" OR "peripheral vascular disease" OR "peripheral angiopathy" 
OR "peripheral angiopathies" OR "Peripheral Arterial Disease"[Mesh] OR 
"peripheral arterial disease" OR "peripheral arterial diseases" OR "peripheral 
artery disease" OR "peripheral artery diseases" OR "Venous Thrombosis"[Mesh] 
OR "venous thrombosis" OR "venous thromboses" OR "deep vein thrombosis" 
OR "deep vein thromboses" OR "Pulmonary Embolism"[Mesh] OR "pulmonary 
embolism" OR "pulmonary embolisms" OR "Dyslipidemias"[Mesh] OR 
dyslipidemia OR dyslipidemias OR "Hypercholesterolemia"[Mesh] OR 
hypercholesterolemia OR hypercholesterolemias OR "Aortic Valve 
Stenosis"[Mesh] OR "Aortic Valve Stenosis" OR "aortic stenosis" OR 
"aortic stenoses" OR "Aneurysm"[Mesh] OR Aneurysm OR aneurysms OR 
Aneurism OR regurgitation OR prolapse) AND (("clinical"[tiab] AND "trial"[tiab]) 
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OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR random*[tiab] OR 
"random allocation"[mesh] OR "therapeutic use"[sh]) NOT (review[pt] OR "Case 
Reports"[pt] OR Comment[pt] OR Editorial[pt] OR Letter[pt] OR "case 
control"[ti] OR polymorphism*[ti] OR allele*[ti] OR "case report"[ti] OR "case 
study"[ti] OR "case series"[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up 
Studies"[Mesh] OR "observational study"[ti] OR "prospective cohort"[ti] OR 
"cohort studies" [Mesh:NoExp] OR "cohort study"[ti] OR "Follow-Up 
Studies"[mesh] OR "Retrospective Studies"[mesh] OR "non-randomized"[ti] OR 
"follow up study"[ti] OR rat[ti] OR rats[ti] OR rabbit*[ti] OR mice[ti] OR mouse[ti] 
OR dog[ti] OR dogs[ti] OR cats[ti] OR animal*[ti] OR (animals[MH] NOT 
humans[MH]) OR "Renal Insufficiency, Chronic"[MeSH] OR renal[ti] 
OR renoprotection[ti] OR (("infant"[MeSH Terms] OR "child"[MeSH Terms] OR 
"adolescent"[MeSH Terms]) NOT "adult"[MeSH Terms]))  
Results: 409  
  
EMBASE (via Scopus) (1823 to present)  
Limits: Article, review, conference papers, journals  
All terms (unless otherwise noted) were searched in "Article Title, 
Abstract, Keywords". Because of character restrictions in Scopus, this 
search was run in parts and assembled using the "Search history".  
 (in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic 
lifestyle changes” OR  “DASH” OR “National Cholesterol Education Program” OR 




"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR 
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR 
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR 
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 




“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR statin 
OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering 
agents” OR  Lipitor OR pravachol OR Zocor OR “lipid lowering agents” 
OR  “HMG-CoA” OR  “bile acid sequestrants” OR  “resins” OR  “fibric acid 
derivatives” OR  “fibrates” OR  “cholesterol absorption inhibitors” 
OR  “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin" 
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR 
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"   
  
Option 1: (clinical AND trial)  
OR   
Option 2: "Clinical Trials" OR "clinical trial" OR random* OR "therapeutic use"  
  
AND NOT   
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(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR 
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*  
 Results 165  
  
  
CINAHL (1981-present)  
All terms were searched in all fields (unless otherwise noted)  
Excluded: MEDLINE Records  
Limited: Research Article  
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic 
lifestyle changes” OR  “DASH” OR “National Cholesterol Education Program” OR 




"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR 
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR 
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR 
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 




“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR statin 
OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering 
agents” OR  Lipitor OR pravachol OR Zocor OR “lipid lowering agents” 
OR  “HMG-CoA” OR  “bile acid sequestrants” OR  “resins” OR  “fibric acid 
derivatives” OR  “fibrates” OR  “cholesterol absorption inhibitors” 
OR  “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin" 
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR 
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"   
  
  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR 
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*  
 Results:  6  
  
PsycINFO  (1872 to present)  
Limits: peer reviewed journals  
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(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic 
lifestyle changes” OR  “DASH” OR “National Cholesterol Education Program” OR 




"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR 
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR 
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR 
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 




“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR statin 
OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering 
agents” OR  Lipitor OR pravachol OR Zocor OR “lipid lowering agents” 
OR  “HMG-CoA” OR  “bile acid sequestrants” OR  “resins” OR  “fibric acid 
derivatives” OR  “fibrates” OR  “cholesterol absorption inhibitors” 
OR  “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin" 
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR 
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"   
  
  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR 
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*    
Results: 0  
  
Academic Search Premier (1980s to present)  
Limit:  Scholarly (Peer Reviewed) Journals  
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic 
lifestyle changes” OR  “DASH” OR “National Cholesterol Education Program” OR 




"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR 
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR 
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR 
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 





“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR statin 
OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering 
agents” OR  Lipitor OR pravachol OR Zocor OR “lipid lowering agents” 
OR  “HMG-CoA” OR  “bile acid sequestrants” OR  “resins” OR  “fibric acid 
derivatives” OR  “fibrates” OR  “cholesterol absorption inhibitors” 
OR  “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin" 
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR 
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"   
  
  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR 
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*  
Results: 0  
  
  
Agricola (1970-present)  
Limits: journal article  
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic 
lifestyle changes” OR  “DASH” OR “National Cholesterol Education Program” OR 




"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR 
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR 
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR 
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 




“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR statin 
OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering 
agents” OR  Lipitor OR pravachol OR Zocor OR “lipid lowering agents” 
OR  “HMG-CoA” OR  “bile acid sequestrants” OR  “resins” OR  “fibric acid 
derivatives” OR  “fibrates” OR  “cholesterol absorption inhibitors” 
OR  “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin" 
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR 




NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR 
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*  
Results: 0  
 
  
CAB Direct (1973-present)  
Limit to Document Type: Journal article and Evidence based research 
articles only  
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic 
lifestyle changes” OR  “DASH” OR “National Cholesterol Education Program” OR 




"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR 
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood 
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR 
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular 
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular 
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR 
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic 




“Antihyperlipidemic medication” OR  “Antihyperlipidemic medications” OR statin 
OR statins OR  “HMG-CoA Reductase” OR  “cholesterol lowering 
agents” OR  Lipitor OR pravachol OR Zocor OR “lipid lowering agents” 
OR  “HMG-CoA” OR  “bile acid sequestrants” OR  “resins” OR  “fibric acid 
derivatives” OR  “fibrates” OR  “cholesterol absorption inhibitors” 
OR  “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin" 
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR 
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"   
  
NOT   
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case 
report" OR comment OR editorial OR letter OR "case control" OR "case study" 
OR "case series" OR "follow-up study" OR "observational study" OR "prospective 
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR 
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*  































































































Appendix 5: SAS Code 
 
proc means data=mdstatin n sum mean max min range std; 
run; 
proc freq data=mdstatin; 
run; 
 
proc means data=LFDstatin n sum mean max min range std; 
run; 
proc freq data=LFDstatin; 
run; 
 
Appendix 6: R Code for Mediterranean Diet 
 





































forest(model2, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,15.5, "Triglycerides") #the first number indicates where the title starts and 
the second number how high in the plot 
text(c(-4,4),14.5,c("Favors Intervention", "Favors Baseline")) 
text(-10,14.5, "Author(s) and Year", pos=4) 
text(8,14.5, "d[95%CI]", pos=4) 
par(op) 
 
forest(model4, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=0.85, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,12.5, "Total Cholesterol") 
text(c(-4,4),11.5,c("Favors Intervention", "Favors Baseline"))  
text(-10,11.5, "Author(s) and Year", pos=4) 
text(8,11.5, "d[95%CI]", pos=4) 
par(op) 
 
forest(model6, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=0.85, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,14.5, "LDL-Cholesterol") 
text(c(-4,4),13.5,c("Favors Intervention", "Favors Baseline"))  
text(-10,13.5, "Author(s) and Year", pos=4) 
text(8,13.5, "d[95%CI]", pos=4) 
par(op) 
 
forest(model8, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=0.85, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,15.5, "HDL-Cholesterol") 
text(c(-4,4),14.5,c("Favors Baseline", "Favors Intervention"))  
text(-10,14.5, "Author(s) and Year", pos=4) 





> regtest(model1, model="lm", data=MedDietStatins) 
 
96 	
> regtest(model3, model="lm", data= MedDietStatins) 
 
> regtest(model5, model="lm", data= MedDietStatins) 
 
> regtest(model7, model="lm", data= MedDietStatins) 
 
#Begg’s 
> ranktest(model1, data= MedDietStatins) 
 
> ranktest(model3, data= MedDietStatins) 
 
> ranktest(model5, data= MedDietStatins) 
 
> ranktest(model7, data= MedDietStatins) 
 
#Trim-and-Fill with Funnel Plots 
> MTGtrim=trimfill(model1, data= MedDietStatins) 
> funnel(MTGtrim) 
 
> MTCtrim=trimfill(model3, data= MedDietStatins) 
> funnel(MTCtrim) 
 
>MLDLtrim=trimfill(model5, data= MedDietStatins) 
>funnel(MLDLtrim) 
 
> MHDLtrim=trimfill(model7, data= MedDietStatins) 
>funnel(MHDLtrim) 
 
Risk of Bias 
 
RanSeq 
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(RanSeq), data=Quality, method=”REML”) 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(RanSeq), data=Quality, method=”REML”) 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(RanSeq), data=Quality, method=”REML”) 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 
mods=~factor(AllCon)-1, data=Quality, method=”REML”) 
> Summary(MHDLbias) 
RanSeq-1 
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1&Outcome==1), mods= ~ 




>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(RanSeq)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(RanSeq)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(AllCon), data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(AllCon), data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(AllCon), data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(AllCon)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(AllCon)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(AllCon)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 
mods=~factor(AllCon)-1, data=Quality, method="REML") 
> Summary(MHDLbias) 
Blinding 
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 




>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(Blinding), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(Blinding), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 





> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(Blinding)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(Blinding)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(Blinding)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(Incomp), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(Incomp), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(Incomp), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 




>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(Incomp)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(Incomp)-1, data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(Select), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(Select), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(Select), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(Select)-1, data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(Select)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(Select)-1, data=Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 




>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(OtherBias), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(OtherBias), data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 




> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1), 
mods=~factor(OtherBias)-1, data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2), 
mods=~factor(OtherBias)-1, data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3), 
mods=~factor(OtherBias)-1, data= Quality, method="REML") 
> Summary(MTGbias) 
 
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4), 






> model9<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Prop_Statins, data= MedDietStatins, method="REML") 
> model9 
 
> model10<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Prop_Statins, data= MedDietStatins, method="REML") 
> model10 
 
> model11<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
Prop_Statins, data= MedDietStatins, method="REML") 
>model11 
 
> model12<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
Prop_Statins, data= MedDietStatins, method="REML") 
> model12 
 
# Length of Intervention 
101 	
> MTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Weeks, data= MedDietStatins, method="REML") 
> MTGwks 
 
> MCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Weeks, data= MedDietStatins, method="REML") 
> MCholwks 
 
> MLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
Weeks, data= MedDietStatins, method="REML") 
> MLDLwks 
 
> MHDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
Weeks, data= MedDietStatins, method="REML") 
> MHDLwks 
 
# Proportion of Females 
> MTGfem<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Female, data= MedDietStatins, method="REML") 
> MTGfem 
 
> MCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Female, data= MedDietStatins, method="REML") 
> MCholfem 
 
> MLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
Female, data= MedDietStatins, method="REML") 
> MLDLfem 
 
> MHDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
Female, data= MedDietStatins, method="REML") 
> MHDLfem 
 
# Region (Europe) 
> MTGregion<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Region==2), data= MedDietStatins, method="REML") 
> MTGregion 
 
> MCholregion<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Region==2), data= MedDietStatins, method="REML") 
> MCholregion 
 
> MLDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
(Region==2), data= MedDietStatins, method="REML") 
> MLDLregion 
 
> MHDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 





> MTGHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods= HTN, 
data= MedDietStatins, method="REML") 
> MTGHTN 
 
> MCholHTN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
HTN, data= MedDietStatins, method="REML") 
> MCholHTN 
 
> MLDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
HTN, data= MedDietStatins, method="REML") 
> MLDLHTN 
 
> MHDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 




> MTGdys<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Dys, 
data= MedDietStatins, method="REML") 
> MTGdys 
 
> MCholdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= Dys, 
data= MedDietStatins, method="REML") 
> MCholdys 
 
> MLDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Dys, 
data= MedDietStatins, method="REML") 
> MLDLdys 
 
#Med Diet and HDL-Cholesterol 
> MHDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= Dys, 
data= MedDietStatins, method="REML") 
> MHDLdys 
 
# Current Smokers 
> MTGSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Smoke, data= MedDietStatins, method="REML") 
> MTGSmoke 
 
> MCholSmoke <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Smoke, data= MedDietStatins, method="REML") 
> MCholSmoke 
 
> MLDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
Smoke, data= MedDietStatins, method="REML") 
> MLDLSmoke 
 
> MHDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 




# Impact Factor 
> MTGIPP<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=IPP, 
data= MedDietStatins, method="REML") 
> MTGIPP 
 
> MCholIPP <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
IPP, data= MedDietStatins, method="REML") 
> MCholIPP 
 
> MLDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= IPP, 
data= MedDietStatins, method="REML") 
> MLDLIPP 
 
> MHDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= IPP, 




> MTGage<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Age, 
data= MedDietStatins, method="REML") 
> MTGage 
 
> MCholage <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Age, data= MedDietStatins, method="REML") 
> MCholage 
 
> MLDLage<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Age, 
data= MedDietStatins, method="REML") 
> MLDLage 
 
> MHDLage <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
Age, data= MedDietStatins, method="REML") 
> MHDLage 
 
#Proportion Fat Intake 
> MTGfat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Fat, 
data= MedDietStatins, method="REML") 
> MTGfat 
 
> MCholfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= Fat, 
data= MedDietStatins, method="REML") 
> MCholfat 
 
> MLDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Fat, 
data= MedDietStatins, method="REML") 
> MLDLfat 
 
> MHDLfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= Fat, 




# Length Between Follow-Up 
> MTGfu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods= 
FollowUp, data= MedDietStatins, method="REML") 
> MTGfu 
 
> MCholfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
FollowUp, data= MedDietStatins, method="REML") 
> MCholfu 
 
> MLDLfu<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
FollowUp, data= MedDietStatins, method="REML") 
> MLDLfu 
 
> MHDLfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
FollowUp, data= MedDietStatins, method="REML") 
> MHDLfu 
 
# Number of Follow-Ups 
> MTGnofu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=NoFollowUp, data= MedDietStatins, method="REML") 
> MTGnofu 
 
> MCholnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
NoFollowUp, data= MedDietStatins, method="REML") 
> MCholnofu 
 
> MLDLnofu<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
NoFollowUp, data= MedDietStatins, method="REML") 
> MLDLnofu 
 
> MHDLnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
NoFollowUp, data= MedDietStatins, method="REML") 
> MHDLnofu 
 
# Provision of Food 
> MTGProv<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Provision, data= MedDietStatins, method="REML") 
> MTGProv 
 
> MCholProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Provision, data= MedDietStatins, method="REML") 
> MCholProv 
 
> MLDLProv<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
Provision, data= MedDietStatins, method="REML") 
> MLDLProv 
 
> MHDLProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 




#Level of Supervision in Intervention 
> MTGInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Interlvl, data= MedDietStatins, method="REML") 
> MTGInterlvl 
 
> MCholInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Interlvl, data= MedDietStatins, method="REML") 
> MCholInterlvl 
 
> MLDLInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
Interlvl, data= MedDietStatins, method="REML") 
> MLDLInterlvl 
 
> MHDLInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
Interlvl, data= MedDietStatins, method="REML") 
> MHDLInterlvl 
 
# Level of Supervision (One-on-one) 
> MTGInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Interlvl==1), data= MedDietStatins, method="REML") 
> MTGInterlvl1 
 
> MCholInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
(Interlvl==1), data= MedDietStatins, method="REML") 
> MCholInterlvl1 
 
> MLDLInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
(Interlvl==1), data= MedDietStatins, method="REML") 
> MLDLInterlvl1 
 
> MHDLInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
(Interlvl==1), data= MedDietStatins, method="REML") 
> MHDLInterlvl1 
 
#Level of Supervision (Small Group) 
> MTGInterlvl2<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Interlvl==2), data= MedDietStatins, method="REML") 
> MTGInterlvl2 
 
> MCholInterlvl2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
(Interlvl==2), data= MedDietStatins, method="REML") 
> MCholInterlvl2 
 
> MLDLInterlvl2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
(Interlvl==2), data= MedDietStatins, method="REML") 
> MLDLInterlvl2 
 
> MHDLInterlvl2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 




# Methodological Quality Score 
> MTGMQ<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=MQ, 
data= MedDietStatins, method="REML") 
> MTGMQ 
 
> MCholMQ <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
MQ, data= MedDietStatins, method="REML") 
> MCholMQ 
 
> MLDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= MQ, 
data= MedDietStatins, method="REML") 
> MLDLMQ 
 
> MHDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= MQ, 
data= MedDietStatins, method="REML") 
> MHDLMQ 
 
# Reported Use of Blood Pressure Medication 
> MTGBPMed<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=BPMed, data= MedDietStatins, method="REML") 
> MTGBPMed 
 
> MCholBPMed <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
BPMed, data= MedDietStatins, method="REML") 
> MCholBPMed 
 
> MLDLBPMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
BPMed, data= MedDietStatins, method="REML") 
> MLDLBPMed 
 
> MHDLBPMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
BPMed, data= MedDietStatins, method="REML") 
> MHDLBPMed 
 
#No Blood Pressure Medication 
> MTGBPMed0<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
(mods=BPMed==0), data= MedDietStatins, method="REML") 
>MTGBPMed0 
 
> MCholBPMed0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(BPMed==0), data= MedDietStatins, method="REML") 
> MCholBPMed0 
 
> MLDLBPMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(BPMed==0), data= MedDietStatins, method="REML") 
> MLDLBPMed0 
 
> MHDLBPMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 




# Reported Use of Other Medications 
> MTGOMed<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 




> MCholOMed <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
OtherMed, data= MedDietStatins, method="REML") 
> MCholOMed 
 
> MLDLOMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
OtherMed, data= MedDietStatins, method="REML") 
> MLDLOMed 
 
> MHDLOMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
OtherMed, data= MedDietStatins, method="REML") 
> MHDLOMed 
 
#No Other Medications 
> MTGOMed0<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(OtherMed==0), data= MedDietStatins, method="REML") 
> MTGOMed0 
 
> MCholOMed0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(OtherMed==0), data= MedDietStatins, method="REML") 
> MCholOMed0 
 
> MLDLOMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(OtherMed==0), data= MedDietStatins, method="REML") 
> MLDLOMed0 
 
> MHDLOMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(OtherMed==0), data= MedDietStatins, method="REML") 
> MHDLOMed0 
 
# Diabetes Mellitus 
> MTGDM<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=DM, 
data= MedDietStatins, method="REML") 
> MTGDM 
 
> MCholDM <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
DM, data= MedDietStatins, method="REML") 
> MCholDM 
 
> MLDLDM<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= DM, 
data= MedDietStatins, method="REML") 
> MLDLDM 
 
> MHDLDM<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= DM, 




# Intervention Sample Size 
> MTGIntN<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods= 
n_post, data= MedDietStatins, method="REML") 
> MTGIntN 
 
> MCholIntN <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
n_post, data= MedDietStatins, method="REML") 
> MCholIntN 
 
> MLDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
n_post, data= MedDietStatins, method="REML") 
> MLDLIntN 
 
> MHDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
n_post, data= MedDietStatins, method="REML") 
> MHDLIntN 
 
# Total Sample Size 
> MTGN<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Ntotal, 
data= MedDietStatins, method="REML") 
> MTGN 
 
> MCholN <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Ntotal, data= MedDietStatins, method="REML") 
> MCholN 
 
> MLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Ntotal, 
data= MedDietStatins, method="REML") 
> MLDLN 
 
> MHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= Ntotal, 
data= MedDietStatins, method="REML") 
> MHDLN 
 
# Participants Lost to Follow-Up 
> MTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Part_lost, data= MedDietStatins, method="REML") 
> MTGlost 
 
> MChollost <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Part_lost, data= MedDietStatins, method="REML") 
> MChollost 
 
> MLDLDlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 




> MHDLlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 




# Non-Diet Control + 3 interventions 
> MTGctrl3<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Controlgrp==3), data= MedDietStatins, method="REML") 
> MTGctrl3 
 
> MCholctrl3 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Controlgrp==3), data= MedDietStatins, method="REML") 
> MCholctrl3 
 
> MLDLctrl3<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Controlgrp==3), data= MedDietStatins, method="REML") 
> MLDLctrl3 
 
> MHDLctrl3<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(Controlgrp==3), data= MedDietStatins, method="REML") 
> MHDLctrl3 
 
# Non-Diet Control Group 
> MTGctrl4<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Controlgrp==4), data= MedDietStatins, method="REML") 
> MTGctrl4 
 
> MCholctrl4 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Controlgrp==4), data= MedDietStatins, method="REML") 
> MCholctrl4 
 
> MLDLDctrl4<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Controlgrp==4), data= MedDietStatins, method="REML") 
> MLDLctrl4 
 
> MHDLctrl4<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(Controlgrp==4), data= MedDietStatins, method="REML") 
> MHDLctrl4 
 
# Experimental Conditions: Diet Control Plus 1 Intervention 
> MTGexp<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Experiment==4), data= MedDietStatins, method="REML") 
> MTGexp 
 
> MCholexp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Experiment==4), data= MedDietStatins, method="REML") 
> MCholexp 
 
> MLDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Experiment==4), data= MedDietStatins, method="REML") 
> MLDLexp 
 
> MHDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 




# Experimental Conditions: Diet Control Plus 2 Interventions 
# Triglycerides 
> MTGexp2<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Experiment==5), data= MedDietStatins, method="REML") 
> MTGexp2 
 
> MCholexp2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Experiment==5), data= MedDietStatins, method="REML") 
> MCholexp2 
 
> MLDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Experiment==5), data= MedDietStatins, method="REML") 
> MLDLexp2 
 
> MHDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(Experiment==5), data= MedDietStatins, method="REML") 
> MHDLexp2 
 
#Experimental Setting (Hospital) 
> MTGset<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(exp_setting==1), data= MedDietStatins, method="REML") 
> MTGset 
 
> MCholset <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(exp_setting==1), data= MedDietStatins, method="REML") 
> MCholset 
 
> MLDLset<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(exp_setting==1), data= MedDietStatins, method="REML") 
> MLDLset 
 
> MHDLset<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(exp_setting==1), data= MedDietStatins, method="REML") 
> MHDLset 
 
# Experimental Setting (Clinic) 
> MTGset2<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(exp_setting==2), data= MedDietStatins, method="REML") 
> MTGset2 
 
> MCholset2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(exp_setting==2), data= MedDietStatins, method="REML") 
> MCholset2 
 
> MLDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 




> MHDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(exp_setting==2), data= MedDietStatins, method="REML") 
> MHDLset2 
 
# Diet Adherence Monitored 
> MTGMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Monitor==1), data= MedDietStatins, method="REML") 
> MTGMonitor 
 
> MCholMonitor <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Monitor==1), data= MedDietStatins, method="REML") 
> MCholMonitor 
 
> MLDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Monitor==1), data= MedDietStatins, method="REML") 
> MLDLMonitor 
 
> MHDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(Monitor==1), data= MedDietStatins, method="REML") 
> MHDLMonitor 
 
 #Weight Loss 
> MTGwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=( 
WtGainLoss ==1), data= MedDietStatins, method="REML") 
> MTGwtloss 
 
> MCholwtloss <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=( 
WtGainLoss ==1), data= MedDietStatins, method="REML") 
> MCholwtloss 
 
> MLDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=( 
WtGainLoss ==1), data= MedDietStatins, method="REML") 
> MLDLwtloss 
 
> MHDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(WtGainLoss==1), data= MedDietStatins, method="REML") 
> MHDLwtloss 
 
#Proportion of Subjects Using ACE Inhibitors 
> MTGace<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=ACEProp, data= MedDietStatins, method="REML") 
> MTGace 
 
> MCholace <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=ACEProp, data= MedDietStatins, method="REML") 
> MCholace 
 
> MLDLace<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 




> MHDLace<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(WtGainLoss==1), data= MedDietStatins, method="REML") 
> MHDLace 
 
#Number of Subjects Using ACE Inhibitors 
> MTGaceno<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=ACENo, data= MedDietStatins, method="REML") 
> MTGaceno 
 
> MCholaceno <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=ACENo, data= MedDietStatins, method="REML") 
> MCholaceno 
 
> MLDLaceno <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=ACENo, data= MedDietStatins, method="REML") 
> MLDLaceno 
 
> MHDLaceno<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=ACENo, data= MedDietStatins, method="REML") 
> MHDLaceno 
 
#Subjects Taking Aspirin 
> MTGaspirin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Aspirin==1), data= MedDietStatins, method="REML") 
> MTGaspirin 
 
> MCholaspirin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Aspirin==1), data= MedDietStatins, method="REML") 
> MCholaspirin 
 
> MLDLaspirin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Aspirin==1), data= MedDietStatins, method="REML") 
> MLDLaspirin 
 
> MHDLaspirin<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(Aspirin==1), data= MedDietStatins, method="REML") 
> MHDLaspirin 
 
#No Subjects Taking Aspirin 
> MTGasp<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Aspirin==0), data= MedDietStatins, method="REML") 
> MTGasp 
 
> MCholasp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Aspirin==0), data= MedDietStatins, method="REML") 
> MCholasp 
 
> MLDLasp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 




> MHDLasp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(Aspirin==0), data= MedDietStatins, method="REML") 
> MHDLasp 
 
#Funding Source (Government) 
> MTGfund<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Funding==1), data= MedDietStatins, method="REML") 
> MTGfund 
 
> MCholfund <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Funding==1), data= MedDietStatins, method="REML") 
> MCholfund 
 
> MLDLfund <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Funding==1), data= MedDietStatins, method="REML") 
> MLDLfund 
 
> MHDLfund<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 




> MTGrecruit<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=(Recruit==3), data= MedDietStatins, method="REML") 
> MTGrecruit 
 
> MCholrecruit <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), 
mods=(Recruit==3), data= MedDietStatins, method="REML") 
> MCholrecruit 
 
> MLDLrecruit <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(Recruit==3), data= MedDietStatins, method="REML") 
> MLDLrecruit 
 
> MHDLrecruit<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), 
mods=(Recruit==3), data= MedDietStatins, method="REML") 
> MHDLrecruit 
 
#Number of Intervention Groups 
> MTGIntgrp<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=NoIntGrps, data= MedDietStatins, method="REML") 
> MTGIntgrp 
 
> MCholIntgrp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
NoIntGrps, data= MedDietStatins, method="REML") 
> MCholIntgrp 
 
> MLDLIntgrp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 




> MHDLIntgrp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
NoIntGrps, data= MedDietStatins, method="REML") 
> MHDLIntgrp 
 
#Subjects Using Insulin or Oral Hypoglycemic Agents 
> MTGinsulin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Insulin/OHA, data= MedDietStatins, method="REML") 
> MTGinsulin 
 
> MCholinsulin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Insulin/OHA, data= MedDietStatins, method="REML") 
> MCholinsulin 
 
> MLDLinsulin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=Insulin/OHA, data= MedDietStatins, method="REML") 
> MLDLinsulin 
 
> MHDLinsulin<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
Insulin/OHA, data= MedDietStatins, method="REML") 
> MHDLinsulin 
 
#No Subjects Using Insulin or Oral Hypoglycemic Agents 
> MTGinsulin0<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
(mods=InsulinOHA==0), data= MedDietStatins, method="REML") 
> MTGinsulin0 
 
> MCholinsulin0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
(InsulinOHA==0), data= MedDietStatins, method="REML") 
> MCholinsulin0 
 
> MLDLinsulin0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 
mods=(InsulinOHA==0), data= MedDietStatins, method="REML") 
> MLDLinsulin0 
 
> MHDLinsulin0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
(InsulinOHA==0), data= MedDietStatins, method="REML") 
> MHDLinsulin0 
 
#Alcohol Intake Recommended  
> MTGETOH<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=ETOH, data= MedDietStatins, method="REML") 
> MTGETOH 
 
> MCholETOH <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
ETOH, data= MedDietStatins, method="REML") 
> MCholETOH 
 
> MLDLETOH <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), 




> MHDLETOH<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
ETOH, data= MedDietStatins, method="REML") 
> MHDLETOH 
 
#Reported Macronutrient Distribution 
> MTGmacro<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=MacroDis, data= MedDietStatins, method="REML") 
> MTGmacro 
 
> MCholmacro <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
MacroDis, data= MedDietStatins, method="REML") 
> MCholmacro 
 
> MLDLmacro <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
MacroDis, data= MedDietStatins, method="REML") 
> MLDLmacro 
 
> MHDLmacro<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 




> MTGyear<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods= Year, 
data= MedDietStatins, method="REML") 
> MTGyear 
 
> MCholyear <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= 
Year, data= MedDietStatins, method="REML") 
> MCholyear 
 
> MLDLyear <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= 
Year, data= MedDietStatins, method="REML") 
> MLDLyear 
 
> MHDLyear<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= 
Year, data= MedDietStatins, method="REML") 
> MHDLyear 
 
#Proportion Taking Statins Min 7%, Max 100%, plus 0%, 10%, 25%, 50%, and 
75% 
> maxstatins = 1-MedDietStatins$Prop_Statins 
> maxstatins 
 
> minstatins=MedDietStatins$Prop_Statins - 0.07 
> minstatins 
 
> threefourthsstatin= MedDietStatins$Prop_Statins - 0.75 
> threefourthsstatin 
 




> quarterstat = MedDietStatins$Prop_Statins - 0.25 
> quarterstat 
 
> tenstat= MedDietStatins$Prop_Statins - 0.1 
> tenstat 
 
> nostat = maxstatins - 1 
> nostat 
 
> MTGStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MTGStat 
 
> MTG75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab= 
paste(Author, Prop_Statins, sep =",")) 
> MTG75Stat 
 
> MTG50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=halfonstatins, data=MedDietStatins, method="REML", slab= paste(Author, 
Prop_Statins, sep =",")) 
> MTG50Stat 
 
> MTG25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=quarterstat, data=MedDietStatins, method="REML", slab= paste(Author, 
Prop_Statins, sep =",")) 
> MTG25stat 
 
> MTG10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Author, 
Prop_Statins, sep =",")) 
>MTG10stat 
 
> TGminstat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minstatins, data=MedDietStatins, method="REML", slab= paste(Author, 
Prop_Statins, sep =",")) 
> TGminstat 
 
> MTGNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference, 
Prop_Statins, sep =",")) 
> MTGNoStat 
 
Maximum, 100% on Statins 
> MTCholMaxStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=maxstatins, data=MedDietStatins, method="REML", slab= 




> MTChol75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MTChol75Stat 
 
> MTChol50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=halfonstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MTChol50Stat 
 
> MTChol25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=quarterstat, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MTChol25stat 
 
> MTChol10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Reference, 
Prop_Statins, sep =",")) 
> MTChol10stat 
 
> MTCholMinStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MTCholMinStat 
 
> MTCholNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference, 
Prop_Statins, sep =",")) 
> MTCholNoStat 
 
> MLDLMaxStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=maxstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MLDLMaxStat 
 
> MLDL75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MLDL75Stat 
 
> MLDL50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=halfonstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MLDL50Stat 
 
> MLDL25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=quarterstat, data=MedDietStatins, method="REML", slab= 




> MLDL10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Reference, 
Prop_Statins, sep =",")) 
> MLDL10stat 
 
> MLDLMinStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MLDLMinStat 
 
> MLDLNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference, 
Prop_Statins, sep =",")) 
> MLDLNoStat 
 
> MHDLMaxStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=maxstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MHDLMaxStat 
 
> MHDL75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MHDL75Stat 
 
> MHDL50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=halfonstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MHDL50Stat 
 
> MHDL25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=quarterstat, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MHDL25stat 
 
> MHDL10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Reference, 
Prop_Statins, sep =",")) 
> HDL10stat 
 
> MHDLMinStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minstatins, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MHDLMinStat 
 
> MHDLNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference, 
Prop_Statins, sep =",")) 
> HDLNoStat 
 
# Min Max for Hypertension 
119 	
> maxHTN = 0.94-MedDietStatins$HTN 
> maxHTN 
 
> minHTN=MedDietStatins$HTN - 0.39 
> minHTN 
 
> MTGHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MTGHTNmax 
 
> MTGHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MTGHTNmin 
 
> MTCholHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MTCholHTNmax 
 
> MTCholHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MTCholHTNmin 
 
> MLDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MLDLHTNmax 
 
> MLDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MLDLHTNmin 
 
> MHDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MHDLHTNmax 
 
> MHDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> MHDLHTNmin 
 
# Min Max for Proportion of Females 
maxFemales = 0.60 -MedDietStatins$Female 
> maxFemales 
 




> MTGFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxFemales, data=MedDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> MTGFemmax 
 
> MTGFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minFemale, data=MedDietStatins, method="REML", slab= 
paste(Reference, Prop_Statins, sep =",")) 
> MTGFemmin 
 
> MCholFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods= 
maxFemales, data=MedDietStatins, method="REML", slab= paste(Reference, 
Female, sep =",")) 
> MCholHTNmax 
 
> MTCholFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minFemale, data=MedDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> MTCholFemmin 
 
> MLDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods= 
maxFemales, data=MedDietStatins, method="REML", slab= paste(Reference, 
Female, sep =",")) 
>MLDLFemmax 
 
> MLDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minFemale, data=MedDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> MLDLFemmin 
 
> HDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods= 
maxFemales, data=MedDietStatins, method="REML", slab= paste(Reference, 
Female, sep =",")) 
> HDLFemmax 
 
> MHDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minFemale, data=MedDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> MHDLFemmin 
 
#Min Max for Dyslipidemia 
> maxDys = 0.72-MedDietStatins$Dys 
> maxDys 
 




> MTGDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxDys, data=MedDietStatins, method="REML", slab= paste(Reference, 
Dys, sep =",")) 
> MTGDysmax 
 
> MTGDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference, 
Dys, sep =",")) 
> MTGDysmin 
 
> MCholDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods= 




> MTCholDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference, 
Dys, sep =",")) 
> MTCholDysmin 
 
> MLDLDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods= 




> MLDLDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference, 
Dys, sep =",")) 
> MLDLDysmin 
 
> MHDLDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods= 




> MHDLDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference, 
Dys, sep =",")) 
> MHDLDysmin 
 
# Min Max for Length of Intervention 
> maxWeeks = 260-MedDietStatins$Weeks 
> maxWeeks 
 
> minWeeks=MedDietStatins$Weeks - 8 
> minWeeks 
 
> MTGWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxWeeks, data=MedDietStatins, method="REML", slab= 




> MTGWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minWeeks, data=MedDietStatins, method="REML", slab= 
paste(Reference, Weeks, sep =",")) 
> MTGWksmin 
 
> MCholWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods= 
maxWeeks, data=MedDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> MCholWksmax 
 
> MCholWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minWeeks, data=MedDietStatins, method="REML", slab= 
paste(Reference, Weeks, sep =",")) 
> MCholWksmin 
 
> MLDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods= 
maxWeeks, data=MedDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> MLDLWksmax 
 
> MLDLWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minWeeks, data=MedDietStatins, method="REML", slab= 
paste(Reference, Weeks, sep =",")) 
> MLDLWksmin 
 
> MHDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods= 
maxWeeks, data=MedDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> MHDLWksmax 
 
> HDLWeeksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minWeeks, data=MedDietStatins, method="REML", slab= 
paste(Reference, Weeks, sep =",")) 
> HDLWeeksmin 
 
# Min Max for Current Smokers 
> maxSmoke = 0.51-MedDietStatins$Smoke 
> maxSmoke 
 
> minSmoke=MedDietStatins$Smoke - 0 
> minSmoke 
 
> MTGSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxSmoke, data=MedDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> MTGSmokemax 
 
> MTGSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minSmoke, data=MedDietStatins, method="REML", slab= 




> MCholSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=maxSmoke, data=MedDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> MCholSmokemax 
 
> MCholSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minSmoke, data=MedDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> MCholSmokemin 
 
> MLDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods= maxSmoke, data=MedDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> MLDLSmokemax 
 
> MLDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minSmoke, data=MedDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> MLDLSmokemin 
 
> MHDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods= maxSmoke, data=MedDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> MHDLSmokemax 
 
> MHDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minSmoke, data=MedDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> MHDLSmokemin 
 
#Min Max for Methodological Quality Score 
> maxMQ = 17 -MedDietStatins$MQ 
> maxMQ 
 
> minMQ=MedDietStatins$MQ - 8 
> minMQ 
 
> MTGMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxMQ, data=MedDietStatins, method="REML", slab= paste(Reference, 
MQ, sep =",")) 
> MTGMQmax 
 
> MTGMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference, 




> MCholMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=maxMQ, data=MedDietStatins, method="REML", slab= paste(Reference, 
MQ, sep =",")) 
> MCholMQmax 
 
> MCholMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference, 
MQ, sep =",")) 
> MCholMQmin 
 
> MLDLMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods= 




> MLDLMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference, 
MQ, sep =",")) 
> MLDLMQmin 
 
> MHDLMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods= 




> MHDLMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference, 
MQ, sep =",")) 
> MHDLMQmin 
 
# Min Max for Number of Follow-Ups 
> maxfu = 10 -MedDietStatins$NoFollowUp 
> maxfu 
 
> minfu=MedDietStatins$NoFollowUp - 1 
> minfu 
 
> MTGfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference, 
NoFollowUp, sep =",")) 
> MTGfumax 
 
> MTGfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference, 
NoFollowUp, sep =",")) 
> MTGfumin 
 
> MCholfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference, 




> MCholfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference, 
NoFollowUp, sep =",")) 
> MCholfumin 
 
> MLDLfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference, 
NoFollowUp, sep =",")) 
> MLDLfumax 
 
> MLDLfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference, 
NoFollowUp, sep =",")) 
> MLDLfumin 
 
> MHDLfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference, 
NoFollowUp, sep =",")) 
> MHDLfumax 
 
> MHDLfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference, 
NoFollowUp, sep =",")) 
> MHDLfumin 
 
# Min Max for Participants Lost to Follow-Up 
> maxlost = 14 -MedDietStatins$Part_lost 
> maxlost 
 
> minlost=MedDietStatins$ Part_lost - 0 
> minlost 
 
> MTGlostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference, 
Part_lost, sep =",")) 
> MTGlostmax 
 
> MTGlostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference, 
Part_lost, sep =",")) 
> MTGlostmin 
 
> MChollostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference, 
Part_lost, sep =",")) 
> MChollostmax 
 
> MChollostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference, 




> MLDLlostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference, 
Part_lost, sep =",")) 
> MLDLlostmax 
 
> MLDLlostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), 
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference, 
Part_lost, sep =",")) 
> MLDLlostmin 
 
> MHDLlostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference, 
Part_lost, sep =",")) 
> MHDLlostmax 
 
> MHDLlostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), 
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference, 





#Length of intervention 
MTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Weeks, 
data=MedDietStatins, method="REML", slab= paste(Author, Weeks, sep =",")) 
MTGwkspred <- predict(MTGwks, newmods=cbind(seq(0, 260,.1))) 
wi = MedDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietTG= subset(MedDietStatins, Diet==1 & Outcome==1) 
plot(dietTG$Weeks,dietTG$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Number of Weeks", 
ylab = "Triglycerides Effect Size (d)", xlim=c(0,260), ylim=c(-2, 0.5)) 
lines(seq(0,260,.1), MTGwkspred$pred, col = "dark red") 
lines(seq(0,260,.1), MTGwkspred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,260,.1), MTGwkspred$ci.ub, lty = "dashed", col="dark red") 
MTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods = Weeks, 
data=MedDietStatins, method="REML", slab= paste(Author, Year, sep =",")) 
MTGwkspred <- predict(MTGwks, newmods=cbind(seq(0,260,.1))) 
MTGwks 
 
MCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=Weeks, 
data=MedDietStatins, method="REML", slab= paste(Author, Weeks, sep =",")) 
MCholwkspred <- predict(MCholwks, newmods=cbind(seq(0,260,.1))) 




size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietTChol= subset(MedDietStatins,Diet==1 & Outcome==2) 
plot(dietTChol$Weeks,dietTChol$d.ex.,pch= 20, col="black", bg = "black", 
cex=size, 
xlab = "Number of Weeks", #Plotting here the observed values of the subsample 
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 260), ylim=c(-2, 0.5)) 
lines(seq(0,260,.1), MCholwkspred$pred, col = "dark red") 
lines(seq(0,260,.1), MCholwkspred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,260,.1), MCholwkspred$ci.ub, lty = "dashed", col="dark red") 
MCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods = 
Weeks, 
data=MedDietStatins, method="REML", slab= paste(Author, Year, sep =",")) 
MCholwkspred <- predict(MCholwks, newmods=cbind(seq(0,260,.1))) 
MCholwks 
 
MLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=Weeks, 
data=MedDietStatins, method="REML", slab= paste(Author, Weeks, sep =",")) 
MLDLwkspred <- predict(MLDLwks, newmods=cbind(seq(0,260,.1))) 
wi = MedDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietLDL= subset(MedDietStatins,Diet==1 & Outcome==3) 
plot(dietLDL$Weeks,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Number of Weeks", #Plotting here the observed values of the subsample 
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 260), ylim=c(-2, 0.5)) 
lines(seq(0,260,.1), MLDLwkspred$pred, col = "dark red") 
lines(seq(0,260,.1), MLDLwkspred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,260,.1), MLDLwkspred$ci.ub, lty = "dashed", col="dark red") 
MLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods = 
Weeks, data=MedDietStatins, method="REML", slab= paste(Author, Year, sep 
=",")) 




MHDLDys<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=Dys, 
data=MedDietStatins, method="REML", slab= paste(Author, Dys, sep =",")) 
MHDLDyspred <- predict(MHDLDys, newmods=cbind(seq(0,1.0,.1))) 
wi = MedDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietHDL= subset(MedDietStatins,Diet==1 & Outcome==4)  
plot(dietHDL$Dys,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Proportion of Dyslipidemia",  
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 1.0), ylim=c(-1, 1.5)) 
lines(seq(0,1.0,.1), MHDLDyspred$pred, col = "dark red") 
lines(seq(0,1.0,.1), MHDLDyspred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,1.0,.1), MHDLDyspred$ci.ub, lty = "dashed", col="dark red") 
MHDLDys<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods = Dys, 
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data=MedDietStatins, method="REML", slab= paste(Author, Year, sep =",")) 
MHDLDyspred <- predict(MHDLDys, newmods=cbind(seq(0,1.0,.1))) 
MHDLDys 
 
#Number of follow-ups 
MTGNofu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=NoFollowUp, 
data=MedDietStatins, method="REML", slab= paste(Author, NoFollowUp, sep 
=",")) 
MTGNofupred <- predict(MTGNofu, newmods=cbind(seq(0,8.0,1))) 
wi = MedDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietTG= subset(MedDietStatins,Diet==1 & Outcome==1)  
plot(dietTG$NoFollowUp,dietTG$d.ex.,pch= 20, col="black", bg = "black", 
cex=size, 
xlab = "Number of Follow-Up Sessions",  
ylab = "Triglycerides Effect Size (d)", xlim=c(0, 8.0), ylim=c(-3, 0.5)) 
lines(seq(0,8.00,1), MTGNofupred$pred, col = "dark red") 
lines(seq(0,8.00,1), MTGNofupred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,8.00,1), MTGNofupred$ci.ub, lty = "dashed", col="dark red") 
MTGNofu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods = 
NoFollowUp, 
data=MedDietStatins, method="REML", slab= paste(Author, NoFollowUp, sep 
=",")) 
MTGpred <- predict(MTGNofu, newmods=cbind(seq(0,8.00,1))) 
MTGNofu 
 
#Number of Subjects Lost to Follow-up 
MTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), 
mods=Part_lost, 
data=MedDietStatins, method="REML", slab= paste(Author, Part_lost, sep =",")) 
MTGlostpred <- predict(MTGlost, newmods=cbind(seq(0,14,0.1))) 
wi = MedDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietTG= subset(MedDietStatins,Diet==1 & Outcome==1)  
plot(dietTG$Part_lost,dietTG$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Number of Subjects Lost to Follow-Up",  
ylab = "Triglycerides Effect Size (d)", xlim=c(0, 15.0), ylim=c(-2, 0.5)) 
lines(seq(0,14.0,.1), MTGlostpred$pred, col = "dark red") 
lines(seq(0,14.0,.1), MTGlostpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,14.0,.1), MTGlostpred$ci.ub, lty = "dashed", col="dark red") 
MTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods = 
Part_lost, 
data=MedDietStatins, method="REML", slab= paste(Author, Part_lost, sep =",")) 





Appendix 7: R Code for Low-Fat Diet 
 
Random-Effect and Fixed-Effect Sizes 
 
#Low Fat Diet without Statins 
> model01<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==1), 
























data=LFDalone, method="FE", slab= paste(Author, Year, sep =", ")) 
> model07 
 
> model08<-rma(d.ex.,var_d.ex.,subset=(Diet ==4&Outcome==4), 
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", ")) 
> model08 
 



























































data=LFDalone, method="FE", slab= paste(Author, Year, sep =", ")) 
> model07 
 
> model08<-rma(d.ex.,var_d.ex.,subset=(Diet ==4&Outcome==4), 






forest(model02, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,19, "Triglycerides")  
text(c(-3,2.5),17.5,c("Favors Intervention", "Favors Baseline"))  
text(-10,17.5, "Author(s) and Year", pos=4) 




forest(model04, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black")  
op<-par(cex=0.85, font=2, col="dark red") 
text (0,20, "Total Cholesterol")  
text(c(-3.5,3.5),18.5,c("Favors Intervention", "Favors Baseline"))  
text(-10,18.5, "Author(s) and Year", pos=4) 
text(8,18.5, "d[95%CI]", pos=4) 
par(op) 
 
forest(model06, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,20, "LDL Cholesterol") 
text(c(-3.5,3.5),18.5,c("Favors Intervention", "Favors Baseline"))  
text(-10,18.5, "Author(s) and Year", pos=4) 
text(8,18.5, "d[95%CI]", pos=4) 
par(op) 
 
forest(model08, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,22, "HDL Cholesterol") 
text(c(-3.5,3.5),20.5,c("Favors Baseline", "Favors Intervention"))  
text(-10,20.5, "Author(s) and Year", pos=4) 
text(8,20.5, "d[95%CI]", pos=4) 
par(op) 
 
forest(model14, xlim=c(-8,8), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black”) 
op<-par(cex=0.85, font=2, col="dark red")  
text (0,30, "Triglycerides")  
text(c(-3,2.5),29,c("Favors Intervention", "Favors Baseline"))  
text(-8,29, "Author(s) and Year", pos=4) 
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text(6.25,29, "d[95%CI]", pos=4) 
par(op) 
 
forest(model16, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black")  
op<-par(cex=0.85, font=2, col="dark red") 
text (0,40, "Total Cholesterol")  
text(c(-4,3.5),39,c("Favors Intervention", "Favors Baseline"))  
text(-10,39, "Author(s) and Year", pos=4) 
text(8,39, "d[95%CI]", pos=4) 
par(op) 
 
forest(model18, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,39, "LDL Cholesterol") 
text(c(-4,3.5),38,c("Favors Intervention", "Favors Baseline"))  
text(-10,38, "Author(s) and Year", pos=4) 
text(8,38, "d[95%CI]", pos=4) 
par(op) 
 
forest(model20, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, 
efac=2, col="dark red", border="black") 
op<-par(cex=1.00, font=2, col="black") 
op<-par(cex=0.85, font=2, col="dark red") 
text (0,39, "HDL Cholesterol") 
text(c(-4,3.5),38,c("Favors Baseline", "Favors Intervention"))  
text(-10,38, "Author(s) and Year", pos=4) 






> regtest(model13, model="lm", data=LFDietStatins) 
 
> regtest(model15, model="lm", data= LFDietStatins) 
 
> regtest(model17, model="lm", data= LFDietStatins) 
 
> regtest(model19, model="lm", data= LFDietStatins) 
 
> regtest(model01, model="lm", data=LFDalone) 
 
> regtest(model03, model="lm", data= LFDalone) 
 
> regtest(model05, model="lm", data= LFDalone) 
 




> ranktest(model13, data= LFDietStatins) 
 
> ranktest(model15, data= LFDietStatins) 
 
> ranktest(model17, data= LFDietStatins) 
 
> ranktest(model19, data= LFDietStatins) 
 
> ranktest(model01, data= LFDalone) 
 
> ranktest(model03, data= LFDalone) 
 
> ranktest(model05, data= LFDalone) 
 
> ranktest(model07, data= LFDalone) 
 
#Trim-and-Fill with Funnel Plots 
>LFTGtrim=trimfill(model13, data= LFDietStatins) 
>funnel(LFTGtrim) 
 
>LFTCtrim=trimfill(model15, data= LFDietStatins) 
>funnel(LFTCtrim) 
 
>LFLDLtrim=trimfill(model17, data= LFDietStatins) 
>funnel(LFLDLtrim) 
 
>LFHDLtrim=trimfill(model19, data= LFDietStatins) 
>funnel(LFHDLtrim)  
 
>LFTGtrim=trimfill(model01, data= LFDalone) 
>funnel(LFTGtrim) 
 
>LFTCtrim=trimfill(model03, data= LFDalone) 
>funnel(LFTCtrim) 
 
>LFLDLtrim=trimfill(model05, data= LFDalone) 
>funnel(LFLDLtrim) 
 
>LFHDLtrim=trimfill(model07, data= LFDalone) 
>funnel(LFHDLtrim)  
 
Risk of Bias 
 
RanSeq-1 
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 




>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(RanSeq)-1, data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(RanSeq)-1, data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(RanSeq), data= LQuality, method="REML") 
> Summary(LTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(RanSeq), data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(RanSeq), data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(AllCon)-1, data= LQuality, method="REML") 
> Summary(LTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(AllCon)-1, data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(AllCon)-1, data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 




>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(AllCon), data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(AllCon), data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(Blinding)-1, data= LQuality, method="REML") 
> Summary(MTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(Blinding)-1, data= LQuality, method="REML") 
> Summary(MTGbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(Blinding)-1, data= LQuality, method="REML") 
> Summary(MTGbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(Blinding), data= LQuality, method="REML") 
> Summary(LTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(Blinding), data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(Blinding), data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 




>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(Incomp)-1, data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(Incomp)-1, data= LQuality, method="REML") 
> Summary(LTGbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(Incomp), data= LQuality, method="REML") 
> Summary(LTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(Incomp), data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(Incomp), data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(Select)-1, data= LQuality, method="REML") 
> Summary(LTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(Select)-1, data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(Select)-1, data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 




>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(Select), data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(Select), data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(OtherBias)-1, data= LQuality, method="REML") 
> Summary(LTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(OtherBias)-1, data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(OtherBias)-1, data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 




> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), 
mods=~factor(OtherBias), data= LQuality, method="REML") 
> Summary(MTGbias) 
 
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2), 
mods=~factor(OtherBias), data= LQuality, method="REML") 
> Summary(LCholbias) 
 
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3), 
mods=~factor(OtherBias), data= LQuality, method="REML") 
> Summary(LLDLbias) 
 
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4), 
mods=~factor(OtherBias), data= LQuality, method="REML") 
> Summary(LHDLbias) 
 
Moderator Analysis Low Fat Diet Without Statins 
 
# Length of Intervention  
> lfdTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), 




> lfdCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), 
mods=Weeks, data= LFDalone, method="REML") 
> lfdCholwks 
 
> lfdLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=Weeks, data= LFDalone, method="REML") 
> lfdLDLwks 
 
> lfdHDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods=Weeks, data= LFDalone, method="REML") 
> lfdHDLwks 
 
# Proprtion of Females  
> lfdTGfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), 
mods=Female, data= LFDalone, method="REML") 
> lfdTGfem 
 
> lfdCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), 
mods=Female, data= LFDalone, method="REML") 
> lfdCholfem 
 
> lfdLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=Female, data= LFDalone, method="REML") 
> lfdLDLfem 
 
> lfdHDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods=Female, data= LFDalone, method="REML") 
> lfdfHDLem 
 
# Region (USA) 
> lfdTGusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), 
mods=(Region==1), data= LFDalone, method="REML") 
> lfdTGusa 
 
> lfdCholusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), 
mods=(Region==1), data= LFDalone, method="REML") 
> lfdCholusa 
 
> lfdLDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=(Region==1), data= LFDalone, method="REML") 
> lfdLDLusa 
 
> lfdHDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods=(Region==1), data= LFDalone, method="REML") 
> lfdHDLusa 
 
# Region (Europe) 
> lfdTGregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), 




> lfdCholregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), 
mods=(Region==2), data= LFDalone, method="REML") 
> lfdCholregion 
 
> lfdLDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=(Region==2), data= LFDalone, method="REML") 
> lfdLDLregion 
 
> lfdHDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods=(Region==2), data= LFDalone, method="REML") 
> lfdHDLregion 
 
# Intervention Sample Size 
> LTGIntN<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
n_post, data= LFDalone, method="REML") 
> LTGIntN 
 
> LCholIntN <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods= 
n_post, data= LFDalone, method="REML") 
> LCholIntN 
 
> LLDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= 
n_post, data= LFDalone, method="REML") 
> LLDLIntN 
 
> LHDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods= 
n_post, data= LFDalone, method="REML") 
> LHDLIntN 
 
# Total Sample Size 
> LTGN<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=Ntotal, 
data= LFDalone, method="REML") 
> LTGN 
 
> LCholN <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods= 
Ntotal, data= LFDalone, method="REML") 
> LCholN 
 
> LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= Ntotal, 
data= LFDalone, method="REML") 
> LLDLN 
 
> LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods= Ntotal, 
data= LFDalone, method="REML") 
> LHDLN 
 
# Proportion of Subjects with Dyslipidemia 
> lfdTGdys<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=Dys, 




> lfdCholdys <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods= 
Dys, data= LFDalone, method="REML") 
> MCholdys 
 
> lfdLDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= Dys, 
data= LFDalone, method="REML") 
> lfdLDLdys 
 
> lfdHDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods= 
Dys, data= LFDalone, method="REML") 
> lfdHDLdys 
 
#Proportion of Subjects with HTN 
> LTGhtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=HTN, 
data= LFDalone, method="REML") 
> LTGhtn 
 
> LCholhtn <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods= 
HTN, data= LFDalone, method="REML") 
> LCholhtn 
 
> LLDLhtn<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= HTN, 
data= LFDalone, method="REML") 
> LLDLhtn 
 
> LHDLhtn<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods= HTN, 
data= LFDalone, method="REML") 
> LHDLhtn 
 
# Mean Age 
> LTGage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= Age, 
data= LFDalone, method="REML") 
> LTGage 
 
> LCholage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=Age, 
data= LFDalone, method="REML") 
> LCholage 
 
> LLDLage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= Age, 
data= LFDalone, method="REML") 
> LLDLage 
 
> LHDLage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= Age, 
data= LFDalone, method="REML") 
> LHDLage 
 
# Carbohydrate intake 
> LTGcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 




> LCholcarb <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods= 
Carbs, data= LFDalone, method="REML") 
> LCholcarb 
 
> LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= 
Carbs, data= LFDalone, method="REML") 
> LLDLcarb 
 
> LHDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods= 
Carbs, data= LFDalone, method="REML") 
> LHDLcarb 
 
# Fat intake 
> LTGfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= Fat, 
data= LFDalone, method="REML") 
> LTGfat 
 
> LCholfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= Fat, 
data= LFDalone, method="REML") 
> LCholfat 
 
> LLDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= Fat, 
data= LFDalone, method="REML") 
> LLDLfat 
 
> LHDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= Fat, 
data= LFDalone, method="REML") 
> LHDLfat 
 
# Protein intake 
> LTGpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Protein, data= LFDalone, method="REML") 
> LTGpro 
 
> LCholpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Protein, data= LFDalone, method="REML") 
> LCholpro 
 
> LLDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
Protein, data= LFDalone, method="REML") 
> LLDLpro 
 
> LHDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Protein, data= LFDalone, method="REML") 
> LHDLpro 
 
# Proportion of Subjects Taking ACE Inhibitors 
> LTGACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 




> LCholACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
PropACE, data= LFDalone, method="REML") 
> LCholACE 
 
> LLDLACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
PropACE, data= LFDalone, method="REML") 
> LLDLACE 
 
> LHDLACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
PropACE, data= LFDalone, method="REML") 
> LHDLACE 
 
# Number of Subjects Taking ACE Inhibitors 
> LTGnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
NoACE, data= LFDalone, method="REML") 
> LTGnoACE 
 
> LCholnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
NoACE, data= LFDalone, method="REML") 
> LCholnoACE 
 
> LLDLnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
NoACE, data= LFDalone, method="REML") 
> LLDLnoACE 
 
> LHDLnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
NoACE, data= LFDalone, method="REML") 
> LHDLnoACE 
 
# Number Subjects with HTN 
> LTGnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
NoHTN, data= LFDalone, method="REML") 
> LTGnohtn 
 
> LCholnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
NoHTN, data= LFDalone, method="REML") 
> LCholnohtn 
 
> LLDLnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
NoHTN, data= LFDalone, method="REML") 
> LLDLnohtn 
 
> LHDLnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
NoHTN, data= LFDalone, method="REML") 
> LHDLnohtn 
 
# Number Subjects with CVD 
> LTGnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 




> LCholnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
NoCVD, data= LFDalone, method="REML") 
> LCholnocvd 
 
> LLDLnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
NoCVD, data= LFDalone, method="REML") 
> LLDLnocvd 
 
> LHDLnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
NoCVD, data= LFDalone, method="REML") 
> LHDLnocvd 
 
# Cholesterol Intake 
> LTGchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Cholesterol, data= LFDalone, method="REML") 
> LTGchol 
 
> LCholchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Cholesterol, data= LFDalone, method="REML") 
> LCholchol 
 
> LLDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
Cholesterol, data= LFDalone, method="REML") 
> LLDLchol 
 
> LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Cholesterol, data= LFDalone, method="REML") 
> LHDLchol 
 
# Fiber Intake 
> LTGFiber <-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Fiber, data= LFDalone, method="REML") 
> LTGFiber 
 
> LCholFiber <-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Fiber, data= LFDalone, method="REML") 
> LCholFiber 
 
> LLDLFiber<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
Fiber, data= LFDalone, method="REML") 
> LLDLFiber 
 
> LHDLFiber<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Fiber, data= LFDalone, method="REML") 
> LHDLFiber 
 
#Moving Constant Technique  
# Length of Intervention (Weeks) 




> wksmin =LFDalone$Weeks - 4 
> wksmin 
 
> LTGwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
wksmax, data= LFDalone, method="REML") 
> LTGwksmax 
 
> LTGwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
wksmin, data=LFDalone, method="REML") 
> LTGwksmin 
 
> LCholwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
wksmax, data=LFDalone, method="REML") 
> LCholwksmax 
 
> LCholwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
wksmin, data=LFDalone, method="REML") 
> LCholwksmin 
 
> LLDLwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
wksmax, data=LFDalone, method="REML") 
> LLDLwksmax 
 
> LLDLwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=wksmin, data=LFDalone, method="REML") 
> LLDLwksmin 
 
> LHDLwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
wksmax, data=LFDalone, method="REML") 
> LHDLwksmax 
 
> LHDLwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 




> femmax = 1.0 - LFDalone$Female 
> femmax 
 
> femmin =LFDalone$Female - 0 
> femmin 
 
> LTGfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
femmax, data= LFDalone, method="REML") 
> LTGfemmax 
 
> LTGfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 




> LCholfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
femmax, data=LFDalone, method="REML") 
> LCholfemmax 
 
> LCholfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
femmin, data=LFDalone, method="REML") 
> LCholfemmin 
 
> LLDLfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
femmax, data=LFDalone, method="REML") 
> LLDLfemmax 
 
> LLDLfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=femmin, data=LFDalone, method="REML") 
> LLDLfemmin 
 
> LHDLfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
femmax, data=LFDalone, method="REML") 
> LHDLfemmax 
 
> LHDLfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
femmin, data=LFDalone, method="REML") 
> LHDLfemmin 
 
# Total Sample Size 
> lNmax = 5850 -LFDalone$Ntotal 
> lNmax 
 
> lNmin =LFDalone$Ntotal - 30 
> lNmin 
 
> LTGNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
lNmax, data= LFDalone, method="REML") 
> LTGNmax 
 
> LTGNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
lNmin, data=LFDalone, method="REML") 
> LTGNmin 
 
> LCholNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
lNmax, data=LFDalone, method="REML") 
> LCholNmax 
 
> LCholNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
lNmin, data=LFDalone, method="REML") 
> LCholNmin 
 
> LLDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 




> LLDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=lNmin, data=LFDalone, method="REML") 
> LLDLNmin 
 
> LHDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
lNmax, data=LFDalone, method="REML") 
> LHDLNmax 
 
> LHDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
lNmin, data=LFDalone, method="REML") 
> LHDLNmin 	
# Age 
> agemax = 69.5 -LFDalone$Age 
> agemax 
 
> agemin =LFDalone$Age - 43 
> agemin 
 
> LTGagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
agemax, data= LFDalone, method="REML") 
> LTGagemax 
 
> LTGagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
agemin, data=LFDalone, method="REML") 
> LTGagemin 
 
> LCholagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
agemax, data=LFDalone, method="REML") 
> LCholagemax 
 
> LCholagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
agemin, data=LFDalone, method="REML") 
> LCholagemin 
 
> LLDLagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
agemax, data=LFDalone, method="REML") 
> LLDLagemax 
 
> LLDLagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=agemin, data=LFDalone, method="REML") 
> LLDLagemin 
 
> LHDLagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
agemax, data=LFDalone, method="REML") 
> LHDLagemax 
 
> LHDLagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 




# Proportion of Subjects with Dyslipidemia 
> Dysmax = 1 -LFDalone$Dys 
> Dysmax 
 
> Dysmin =LFDalone$Dys - 0 
> Dysmin 
 
> LTGdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Dysmax, data= LFDalone, method="REML") 
> LTGdysmax 
 
> LTGdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Dysmin, data=LFDalone, method="REML") 
> LTGdysmin 
 
> LCholdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Dysmax, data=LFDalone, method="REML") 
> LCholdysmax 
 
> LCholdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Dysmin, data=LFDalone, method="REML") 
> LCholdysmin 
 
> LLDLdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
Dysmax, data=LFDalone, method="REML") 
> LLDLdysmax 
 
> LLDLdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=Dysmin, data=LFDalone, method="REML") 
> LLDLdysmin 
 
> LHDLdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Dysmax, data=LFDalone, method="REML") 
> LHDLdysmax 
 
> LHDLdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Dysmin, data=LFDalone, method="REML") 
> LHDLdysmin 	
# Proportion of Subjects with Hypertension 
> HTNmax = .946 -LFDalone$HTN 
> HTNmax 
 
> HTNmin =LFDalone$HTN - .35 
> HTNmin 
 
> LTGHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 




> LTGHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
HTNmin, data=LFDalone, method="REML") 
> LTGHTNmin 
 
> LCholHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
HTNmax, data=LFDalone, method="REML") 
> LCholHTNmax 
 
> LCholHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
HTNmin, data=LFDalone, method="REML") 
> LCholHTNmin 
 
> LLDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
HTNmax, data=LFDalone, method="REML") 
> LLDLHTNmax 
 
> LLDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=HTNmin, data=LFDalone, method="REML") 
> LLDLHTNmin 
 
> LHDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
HTNmax, data=LFDalone, method="REML") 
> LHDLHTNmax 
 
> LHDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
HTNmin, data=LFDalone, method="REML") 
> LHDLHTNmin 
 
#Number of Subjects with Hypertension 
> NHTNmax = 328 -LFDalone$NoHTN 
> NHTNmax 
 
> NHTNmin =LFDalone$NoHTN - 0 
> NHTNmin 
 
> LTGNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
NHTNmax, data= LFDalone, method="REML") 
> LTGNHTNmax 
 
> LTGNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
NHTNmin, data=LFDalone, method="REML") 
> LTGNHTNmin 
 
> LCholNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), 
mods= NHTNmax, data=LFDalone, method="REML") 
> LCholNHTNmax 
 
> LCholNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 




> LLDLNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods= NHTNmax, data=LFDalone, method="REML") 
> LLDLNHTNmax 
 
> LLDLNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=NHTNmin, data=LFDalone, method="REML") 
> LLDLNHTNmin 
 
> LHDLNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods= NHTNmax, data=LFDalone, method="REML") 
> LHDLNHTNmax 
 
> LHDLNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
NHTNmin, data=LFDalone, method="REML") 
> LHDLNHTNmin 	
# Fat Intake 
> fatmax = .382 -LFDalone$Fat 
> fatmax 
 
> fatmin =LFDalone$Fat - .246 
> fatmin 
 
> LTGfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
fatmax, data= LFDalone, method="REML") 
> LTGHfatmax 
 
> LTGHfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
fatmin, data=LFDalone, method="REML") 
> LTGfatmin 
 
> LCholfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
fatmax, data=LFDalone, method="REML") 
> LCholfatmax 
 
> LCholfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
fatmin, data=LFDalone, method="REML") 
> LCholfatmin 
 
> LLDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
fatmax, data=LFDalone, method="REML") 
> LLDLfatmax 
 
> LLDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=fatmin, data=LFDalone, method="REML") 
> LLDLfatmin 
 
> LHDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 




> LHDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
fatmin, data=LFDalone, method="REML") 
> LHDLfatmin 	
# Protein Intake 
> promax = .222 -LFDalone$Protein 
> promax 
 
> promin =LFDalone$Protein - .1 
> promin 
 
> LTGpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
promax, data= LFDalone, method="REML") 
> LTGHpromax 
 
> LTGpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
promin, data=LFDalone, method="REML") 
> LTGpromin 
 
> LCholpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
promax, data=LFDalone, method="REML") 
> LCholpromax 
 
> LCholpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
promin, data=LFDalone, method="REML") 
> LCholpromin 
 
> LLDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
promax, data=LFDalone, method="REML") 
> LLDLpromax 
 
> LLDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=promin, data=LFDalone, method="REML") 
> LLDLpromin 
 
> LHDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods=promax, data=LFDalone, method="REML") 
> LHDLpromax 
 
> LHDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
promin, data=LFDalone, method="REML") 
> LHDLpromin 	
# Proportion of Subjects Taking ACE inhibitors 
> ACEmax = .54 - LFDalone$PropACE 
> ACEmax 
 




> LTGACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
ACEmax, data= LFDalone, method="REML") 
> LTGHACEmax 
 
> LTGHACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
ACEmin, data=LFDalone, method="REML") 
> LTGACEmin 
 
> LCholACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
ACEmax, data=LFDalone, method="REML") 
> LCholACEmax 
 
> LCholACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
ACEmin, data=LFDalone, method="REML") 
> LCholACEmin 
 
> LLDLACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
ACEmax, data=LFDalone, method="REML") 
> LLDLACEmax 
 
> LLDLACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=ACEmin, data=LFDalone, method="REML") 
> LLDLACEmin 
 
> LHDLACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods=ACEmax, data=LFDalone, method="REML") 
> LHDLACEmax 
 
> LHDLACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
ACEmin, data=LFDalone, method="REML") 
> LHDLACEmin 	
# Number of Subjects Taking ACE inhibitors 
> NACEmax = 114 - LFDalone$NoACE 
> NACEmax 
 
> NACEmin =LFDalone$NoACE - 0 
> NACEmin 
 
> LTGNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
NACEmax, data= LFDalone, method="REML") 
> LTGHNACEmax 
 
> LTGHNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), 
mods= NACEmin, data=LFDalone, method="REML") 
> LTGNACEmin 
 
> LCholNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), 




> LCholNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
NACEmin, data=LFDalone, method="REML") 
> LCholNACEmin 
 
> LLDLNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods= NACEmax, data=LFDalone, method="REML") 
> LLDLNACEmax 
 
> LLDLNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=NACEmin, data=LFDalone, method="REML") 
> LLDLNACEmin 
 
> LHDLNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), 
mods=NACEmax, data=LFDalone, method="REML") 
> LHDLNACEmax 
 
> LHDLNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
NACEmin, data=LFDalone, method="REML") 
> LHDLNACEmin 	
# Number of Subjects with Cardiovascular Disease 
> CVDmax = 107 - LFDalone$NoCVD 
> CVDmax 
 
> CVDmin =LFDalone$NoCVD - 0 
> CVDmin 
 
> LTGCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
CVDmax, data= LFDalone, method="REML") 
> LTGCVDmax 
 
> LTGCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
CVDmin, data=LFDalone, method="REML") 
> LTGCVDmin 
 
> LCholCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
CVDmax, data=LFDalone, method="REML") 
> LCholCVDmax 
 
> LCholCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
CVDmin, data=LFDalone, method="REML") 
> LCholCVDmin 
 
> LLDLCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
CVDmax, data=LFDalone, method="REML") 
> LLDLCVDmax 
 
> LLDLCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 




> LHDLCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
CVDmax, data=LFDalone, method="REML") 
> LHDLCVDmax 
 
> LHDLCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
CVDmin, data=LFDalone, method="REML") 
> LHDLCVDmin 	
# Cholesterol Intake 
> Cmax = 300 - LFDalone$Cholesterol 
> Cmax 
 
> Cmin =LFDalone$Cholesterol - 28 
> Cmin 
 
> LTGCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Cmax, data= LFDalone, method="REML") 
> LTGCmax 
 
> LTGCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Cmin, data=LFDalone, method="REML") 
> LTGCmin 
 
> LCholCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Cmax, data=LFDalone, method="REML") 
> LCholCmax 
 
> LCholCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Cmin, data=LFDalone, method="REML") 
> LCholCmin 
 
> LLDLCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
Cmax, data=LFDalone, method="REML") 
> LLDLCmax 
 
> LLDLCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=Cmin, data=LFDalone, method="REML") 
> LLDLCmin 
 
> LHDLCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Cmax, data=LFDalone, method="REML") 
> LHDLCmax 
 
> LHDLCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Cmin, data=LFDalone, method="REML") 
> LHDLCmin 	
# Fiber Intake 




> Fmin =LFDalone$Fiber – 23.6 
> Fmin 
 
> LTGFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
Fmax, data= LFDalone, method="REML") 
> LTGFmax 
 




> LCholFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Fmax, data=LFDalone, method="REML") 
> LCholFmax 
 
> LCholFmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
Fmin, data=LFDalone, method="REML") 
> LCholFmin 
 
> LLDLFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
Fmax, data=LFDalone, method="REML") 
> LLDLFmax 
 
> LLDLFmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), 
mods=Fmin, data=LFDalone, method="REML") 
> LLDLFmin 
 
> LHDLFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Fmax, data=LFDalone, method="REML") 
> LHDLFmax 
 
> LHDLFmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 
Fmin, data=LFDalone, method="REML") 
> LHDLFmin 	
#Region Study Conducted 
> LTGUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
(Region==1), data= LFDalone, method="REML") 
> LTGUSA 
 
> LCholUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
(Region==1), data=LFDalone, method="REML") 
> LCholUSA 
 
> LLDLUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
(Region==1), data=LFDalone, method="REML") 
> LLDLUSA 
 
> LHDLUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 




> LTGeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= 
(Region==4), data= LFDalone, method="REML") 
> LTGeuro 
 
> LCholeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= 
(Region==4), data=LFDalone, method="REML") 
> LCholeuro 
 
> LLDLeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= 
(Region==4), data=LFDalone, method="REML") 
> LLDLeuro 
 
> LHDLeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= 




Moderator Analysis Low Fat Diet with Statins 
 
# Length of Intervention  
> lfdTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=Weeks, data= LFDietStatins, method="REML") 
> lfdTGwks 
 
> lfdCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=Weeks, data= LFDietStatins, method="REML") 
> lfdCholwks 
 
> lfdLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=Weeks, data= LFDietStatins, method="REML") 
> lfdLDLwks 
 
> lfdHDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=Weeks, data= LFDietStatins, method="REML") 
> lfdHDLwks 
 
# Proprtion of Females  
> lfdTGfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=Female, data= LFDietStatins, method="REML") 
> lfdTGfem 
 
> lfdCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=Female, data= LFDietStatins, method="REML") 
> lfdCholfem 
 
> lfdLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 




> lfdHDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=Female, data= LFDietStatins, method="REML") 
> lfdfHDLem 
 
# Region (USA) 
> lfdTGusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Region==1), data= LFDietStatins, method="REML") 
> lfdTGusa 
 
> lfdCholusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=(Region==1), data= LFDietStatins, method="REML") 
> lfdCholusa 
 
> lfdLDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=(Region==1), data= LFDietStatins, method="REML") 
> lfdLDLusa 
 
> lfdHDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=(Region==1), data= LFDietStatins, method="REML") 
> lfdHDLusa 
 
# Region (Europe) 
> lfdTGregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Region==2), data= LFDietStatins, method="REML") 
> lfdTGregion 
 
> lfdCholregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=(Region==2), data= LFDietStatins, method="REML") 
> lfdCholregion 
 
> lfdLDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=(Region==2), data= LFDietStatins, method="REML") 
> lfdLDLregion 
 
> lfdHDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 




> lfdTGHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=HTN, 
data= LFDietStatins, method="REML") 
> lfdTGHTN 
 
> lfdColHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=HTN, 
data= LFDietStatins, method="REML") 
> lfdColHTN 
 
> lfdLDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 




> lfdHDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=HTN, data= LFDietStatins, method="REML") 
> lfdHDLHTN 
 
# Current Smokers 
> lfdTGSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
Smoke, data= LFDietStatins, method="REML") 
> lfdTGSmoke 
 
> lfdCholSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=Smoke, data= LFDietStatins, method="REML") 
> lfdCholSmoke 
 
> lfdLDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
Smoke, data= LFDietStatins, method="REML") 
> lfdLDLSmoke 
 
> lfdHDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 
Smoke, data= LFDietStatins, method="REML") 
> lfdHDLSmoke 
 
# Impact Factor 
> lfdTGIPP<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), mods=IPP, 
data= LFDietStatins, method="REML") 
> lfdTGIPP 
 
> lfdCholIPP <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
IPP, data= LFDietStatins, method="REML") 
> lfdCholIPP 
 
> lfdLDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= IPP, 
data= LFDietStatins, method="REML") 
> lfdLDLIPP 
 
> lfdHDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
IPP, data= LFDietStatins, method="REML") 
> lfdHDLIPP 
 
# Statin Dose 
> lfdTGdose<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=Dose, data= LFDietStatins, method="REML") 
> lfdTGdose 
 
> lfdCholdose <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Dose, data= LFDietStatins, method="REML") 
> lfdCholdose 
 
> lfdLDLdose<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 




> lfdHDLdose<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Dose, data= LFDietStatins, method="REML") 
> lfdHDLdose 
 
# Methodological Quality Score 
> lfdTGMQ<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=MQ, 
data= LFDietStatins, method="REML") 
> lfdTGMQ 
 
> lfdCholMQ <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 




> lfdLDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= MQ, 
data= LFDietStatins, method="REML") 
> lfdLDLMQ 
 
> lfdHDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
MQ, data= LFDietStatins, method="REML") 
> lfdHDLMQ 
 
# Mean Age 
> LTGage<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Age, 
data= LFDietStatins, method="REML") 
> LTGage 
 
> LCholage <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Age, data= LFDietStatins, method="REML") 
> LCholage 
 
> LLDLage<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= Age, 
data= LFDietStatins, method="REML") 
> LLDLage 
 
> LHDLage <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 




> LTGfat<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Fat, 
data= LFDietStatins, method="REML") 
> LTGfat 
 
> LCholfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= Fat, 
data= LFDietStatins, method="REML") 
> LCholfat 
 
> LLDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= Fat, 




> LHDLfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= Fat, 




> LTGcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Carbs, 
data= LFDietStatins, method="REML") 
> LTGcarb 
 
> LCholcarb <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Carbs, data= LFDietStatins, method="REML") 
> LCholcarb 
 
> LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
Carbs, data= LFDietStatins, method="REML") 
> LLDLcarb 
 
> LHDLcarb <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 




> LTGpro<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
Protein, data= LFDietStatins, method="REML") 
> LTGpro 
 
> LCholpro <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Protein, data= LFDietStatins, method="REML") 
> LCholpro 
 
> LLDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
Protein, data= LFDietStatins, method="REML") 
> LLDLpro 
 
> LHDLpro <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Protein, data= LFDietStatins, method="REML") 
> LHDLpro 
 
# Length Follow-Up 
> LTGfu<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
FollowUp, data= LFDietStatins, method="REML") 
> LTGfu 
 
> LCholfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
FollowUp, data= LFDietStatins, method="REML") 
> LCholfu 
 
> LLDLfu<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 




> LHDLfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
FollowUp, data= LFDietStatins, method="REML") 
> LHDLfu 
 
# Number of Follow-Ups 
> LTGnofu<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=NoFollowUp, data= LFDietStatins, method="REML") 
> LTGnofu 
 
> LCholnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
NoFollowUp, data= LFDietStatins, method="REML") 
> LCholnofu 
 
> LLDLnofu<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
NoFollowUp, data= LFDietStatins, method="REML") 
> LLDLnofu 
 
> LHDLnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
NoFollowUp, data= LFDietStatins, method="REML") 
> LHDLnofu 
 
# Provision of Food 
> LTGProv<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=Provision, data= LFDietStatins, method="REML") 
> LTGProv 
 
> LCholProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Provision, data= LFDietStatins, method="REML") 
> LCholProv 
 
> LLDLProv<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
Provision, data= LFDietStatins, method="REML") 
> LLDLProv 
 
> LHDLProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Provision, data= LFDietStatins, method="REML") 
> LHDLProv 
 
# Intervention Level 
> LTGInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=Interlvl, data= LFDietStatins, method="REML") 
> LTGInterlvl 
 
> LCholInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Interlvl, data= LFDietStatins, method="REML") 
> LCholInterlvl 
 
> LLDLInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 




> LHDLInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Interlvl, data= LFDietStatins, method="REML") 
> LHDLInterlvl 
 
# Intervention Level, One-on-One 
> LTGInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Interlvl==1), data= LFDietStatins, method="REML") 
> LTGInterlvl1 
 
> LCholInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
(Interlvl==1), data= LFDietStatins, method="REML") 
> LCholInterlvl1 
 
> LLDLInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
(Interlvl==1), data= LFDietStatins, method="REML") 
> LLDLInterlvl1 
 
> LHDLInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
(Interlvl==1), data= LFDietStatins, method="REML") 
> LHDLInterlvl1 
 
# Intervention Sample Size 
> LTGIntN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
n_post, data= LFDietStatins, method="REML") 
> LTGIntN 
 
> LCholIntN <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
n_post, data= LFDietStatins, method="REML") 
> LCholIntN 
 
> LLDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
n_post, data= LFDietStatins, method="REML") 
> LLDLIntN 
 
> LHDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
n_post, data= LFDietStatins, method="REML") 
> LHDLIntN 
 
# Total Sample Size 
> LTGN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Ntotal, 
data= LFDietStatins, method="REML") 
> LTGN 
 
> LCholN <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Ntotal, data= LFDietStatins, method="REML") 
> LCholN 
 
> LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= Ntotal, 




> LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= Ntotal, 
data= LFDietStatins, method="REML") 
> LHDLN 
 
# Participants Lost 
> LTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=Part_lost, data= LFDietStatins, method="REML") 
> LTGlost 
 
> LChollost <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= 
Part_lost, data= LFDietStatins, method="REML") 
> LChollost 
 
> LLDLDlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
Part_lost, data= LFDietStatins, method="REML") 
> LLDLDlost 
 
> LHDLlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Part_lost, data= LFDietStatins, method="REML") 
> LHDLlost 
 
# Experimental Conditions: Diet control plus 1 intervention 
> LTGexp<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Experiment==4), data= LFDietStatins, method="REML") 
> LTGexp 
 
> LCholexp <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(Experiment==4), data= LFDietStatins, method="REML") 
> LCholexp 
 
> LLDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(Experiment==4), data= LFDietStatins, method="REML") 
> LLDLexp 
 
> LHDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(Experiment==4), data= LFDietStatins, method="REML") 
> LHDLexp 
 
# Experimental Conditions: Diet control plus 3 interventions 
> LTGexp2<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Experiment==6), data= LFDietStatins, method="REML") 
> LTGexp2 
 
> LCholexp2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(Experiment==6), data= LFDietStatins, method="REML") 
> LCholexp2 
 
> LLDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 




> LHDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 




# Experimental Setting - Clinic 
> LTGset2<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(exp_setting==2), data= LFDietStatins, method="REML") 
> LTGset2 
 
> LCholset2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(exp_setting==2), data= LFDietStatins, method="REML") 
> LCholset2 
 
> LLDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(exp_setting==2), data= LFDietStatins, method="REML") 
> LLDLset2 
 
> LHDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(exp_setting==2), data= LFDietStatins, method="REML") 
> LHDLset2 
 
# Diet Adherence Monitored (yes) 
> LTGMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Monitor==1), data= LFDietStatins, method="REML") 
> LTGMonitor 
 
> LCholMonitor <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(Monitor==1), data= LFDietStatins, method="REML") 
> LCholMonitor 
 
> LLDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(Monitor==1), data= LFDietStatins, method="REML") 
> LLDLMonitor 
 
> LHDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(Monitor==1), data= LFDietStatins, method="REML") 
> LHDLMonitor 
 
# Weight Loss 
> LTGwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=( 
WtGainLoss ==1), data= LFDietStatins, method="REML") 
> LTGwtloss 
 
> LCholwtloss <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(WtGainLoss==1), data= LFDietStatins, method="REML") 
> LCholwtloss 
 
> LLDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 




> LHDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(WtGainLoss==1), data= LFDietStatins, method="REML") 
> LHDLwtloss 
 
# Weight Maintenance 
> LTGwtmain<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(WtGainLoss==3), data= LFDietStatins, method="REML") 
> LTGwtmain 
 
> LCholwtmain <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(WtGainLoss==3), data= LFDietStatins, method="REML") 
> LCholwtmain 
 
> LLDLwtmain<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(WtGainLoss==3), data= LFDietStatins, method="REML") 
> LLDLwtmain 
 
> LHDLwtmain<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(WtGainLoss==3), data= LFDietStatins, method="REML") 
> LHDLwtmain 
 
# Weight Change Not Reported 
> LTGwtNR<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=( 
WtGainLoss ==4), data= LFDietStatins, method="REML") 
> LTGwtNR 
 
> LCholwtNR <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=( 
WtGainLoss ==4), data= LFDietStatins, method="REML") 
> LCholwtNR 
 
> LLDLwtNR<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=( 
WtGainLoss ==4), data= LFDietStatins, method="REML") 
> LLDLwtNR 
 
> LHDLwtNR<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 




> LTGYear<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Year, 
data= LFDietStatins, method="REML") 
> LTGYear 
 
> LCholYear <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=Year, data= LFDietStatins, method="REML") 
> LCholYear 
 
> LLDLYear<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 




> LHDLYear<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=Year, data= LFDietStatins, method="REML") 
> LHDLYear 
 
#Funding Source - Government 
> LTGfund<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Funding==1), data= LFDietStatins, method="REML") 
> LTGfund 
 
> LCholfund <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mod=(Funding==1), data= LFDietStatins, method="REML") 
> LCholfund 
 
> LLDLfund<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(Funding==1), data= LFDietStatins, method="REML") 
> LLDLfund 
 
> LHDLfund<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(Funding==1), data= LFDietStatins, method="REML") 
> LHDLfund 
 
#Funding Source – Private Funder 
> LTGfund2<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Funding==3), data= LFDietStatins, method="REML") 
> LTGfund2 
 
> LCholfund2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mod=(Funding==3), data= LFDietStatins, method="REML") 
> LCholfund2 
 
> LLDLfund2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(Funding==3), data= LFDietStatins, method="REML") 
> LLDLfund2 
 
> LHDLfund2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(Funding==3), data= LFDietStatins, method="REML") 
> LHDLfund2 
 
#Number of Intervention Groups 
> LTGnointgrp<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=NoIntGrps, data= LFDietStatins, method="REML") 
> LTGnointgrp 
 
> LCholnointgrp <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
NoIntGrps,  data= LFDietStatins, method="REML") 
> LCholnointgrp 
 
> LLDLnointgrp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 




> LHDLnointgrp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
NoIntGrps,  data= LFDietStatins, method="REML") 
> LHDLnointgrp 
 
#Proportion of Subjects with Cardiovascular Disease 
> LTGcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=CVDProp, data= LFDietStatins, method="REML") 
> LTGcvdprop 
 
> LCholcvdprop <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
CVDProp,  data= LFDietStatins, method="REML") 
> LCholcvdprop 
 
> LLDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
CVDProp,  data= LFDietStatins, method="REML") 
> LLDLcvdprop 
 
> LHDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
CVDProp,  data= LFDietStatins, method="REML") 
> LHDLcvdprop 
 
#Number of Subjects with Cardiovascular Disease 
> LTGcvdno<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=CVDNo, data= LFDietStatins, method="REML") 
> LTGcvdno 
 
> LCholcvdno <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
CVDNo,  data= LFDietStatins, method="REML") 
> LCholcvdno 
 
> LLDLcvdno<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
CVDNo,  data= LFDietStatins, method="REML") 
> LLDLcvdno 
 
> LHDLcvdno<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
CVDNo,  data= LFDietStatins, method="REML") 
> LHDLcvdno 
 
# Subjects Taking Oral Contraceptives or on Hormone Replacement Therapy 
> LTGcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=OC_HRT, data= LFDietStatins, method="REML") 
> LTGcvdprop 
 
> LCholcvdprop <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
OC_HRT,  data= LFDietStatins, method="REML") 
> LCholcvdprop 
 
> LLDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 




> LHDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
OC_HRT,  data= LFDietStatins, method="REML") 
> LHDLcvdprop 
 
# Recommended Sodium Intake 
> LTGNa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
Sodium, data= LFDietStatins, method="REML") 
> LTGNa 
 
> LCholNa <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
Sodium,  data= LFDietStatins, method="REML") 
> LCholNa 
 
> LLDLNa<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
Sodium,  data= LFDietStatins, method="REML") 
> LLDLNa 
 
> LHDLNa<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Sodium,  data= LFDietStatins, method="REML") 
> LHDLNa 
 
# Recommended Cholesterol Intake 
> LTGchol<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
Cholesterol, data= LFDietStatins, method="REML") 
> LTGchol 
 
> LCholchol <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
Cholesterol,  data= LFDietStatins, method="REML") 
> LCholchol 
 
> LLDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=Cholesterol,  data= LFDietStatins, method="REML") 
> LLDLchol 
 
> LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Cholesterol,  data= LFDietStatins, method="REML") 
> LHDLchol 
 
# Recommended Fiber Intake 
> LTGfiber<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= Fiber, 
data= LFDietStatins, method="REML") 
> LTGfiber 
 
> LCholfiber <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
Fiber,  data= LFDietStatins, method="REML") 
> LCholfiber 
 
> LLDLfiber<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 




> LHDLfiber<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
Fiber,  data= LFDietStatins, method="REML") 
> LHDLfiber 
 
# Reported Macronutrient Distribution 
> LTGmacro<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
MacroDis, data= LFDietStatins, method="REML") 
> LTGmacro 
 
> LCholmacro <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
MacroDis,  data= LFDietStatins, method="REML") 
> LCholmacro 
 
> LLDLmacro<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= 
MacroDis,  data= LFDietStatins, method="REML") 
> LLDLmacro 
 
> LHDLmacro<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= 
MacroDis,  data= LFDietStatins, method="REML") 
> LHDLmacro 
 
#No Reported Macronutrient Distribution 
> LTGmacro1<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
(MacroDis==0), data= LFDietStatins, method="REML") 
 
> LCholmacro1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod= 
(MacroDis==0),  data= LFDietStatins, method="REML") 
 
> LLDLmacro1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(MacroDis==0),  data= LFDietStatins, method="REML") 
 
> LHDLmacro1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(MacroDis==0),  data= LFDietStatins, method="REML") 
 
#Min Max for Statin Dosage 
> maxdose = 80 -LFDietStatins$Dose 
> maxdose 
 
> mindose = LFDietStatins$Dose - 5 
> mindose 
 
> LTGdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=maxdose, data=LFDietStatins, method="REML", slab= paste(Reference, 
Dose, sep =",")) 
> LTGdosemax 
 
> LTGdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference, 




> LCholdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LCholdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference, 
Dose, sep =",")) 
> LCholdosemin 
 
> LLDLdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 




> LLDLdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference, 
Dose, sep =",")) 
> LLDLdosemin 
 
> LHDLdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




> LHDLdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference, 
Dose, sep =",")) 
> LHDLdosemin 
 
#Min Max for Hypertension 
> lmaxHTN = .72 -LFDietStatins$HTN 
> lmaxHTN 
 
> lminHTN=LFDietStatins$HTN - 0.215 
> lminHTN 
 
> LTGHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> LTGHTNmax 
 
> LTGHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 




> LCholHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> LCholHTNmax 
 
> LCholHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), 
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> LCholHTNmin 
 
> LLDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> LLDLHTNmax 
 
> LLDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> LLDLHTNmin 
 
> LHDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> LHDLHTNmax 
 
> LHDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference, 
HTN, sep =",")) 
> LHDLHTNmin 
 
#Min Max for Females 
>lmaxFemale = 1 - LFDietStatins$Female 
> lmaxFemale 
 
> lminFemale = LFDietStatins$Female - 0.0 
> lminFemale 
 
> LTGFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference, 
Female, sep =",")) 
> LTGFemmax 
 
> LTGFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lminFemale, data=LFDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> LTGFemmin 
 
> LCholFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference, 




> LCholFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=lminFemale, data=LFDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> LCholFemmin 
 
> LDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference, 
Female, sep =",")) 
> LDLFemmax 
 
> LDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lminFemale, data=LFDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> LDLFemmin 
 
> LHDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference, 
Female, sep =",")) 
> LHDLFemmax 
 
> LHDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=lminFemale, data=LFDietStatins, method="REML", slab= 
paste(Reference, Female, sep =",")) 
> LHDLFemmin 
 
#Min Max for Length of Intervention 
> lmaxWeeks = 208-LFDietStatins$Weeks 
> lmaxWeeks 
 
> lminWeeks=LFDietStatins$Weeks - 3 
> lminWeeks 
 
> LTGWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lmaxWeeks, data=LFDietStatins, method="REML", slab= 
paste(Reference, Weeks, sep =",")) 
> LTGWksmax 
 
> LTGWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> LTGWksmin 
 
> LCholWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 
lmaxWeeks, data=LFDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> LCholWksmax 
 
> LCholWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference, 




> LLDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
lmaxWeeks, data=LFDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> LLDLWksmax 
 
> LLDLWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> LLDLWksmin 
 
> LHDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 
lmaxWeeks, data=LFDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> LHDLWksmax 
 
> LHDLWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference, 
Weeks, sep =",")) 
> LHDLWksmin 
 
#Min Max for Smokers 
> lmaxSmoke = 0.50-LFDietStatins$Smoke 
> lmaxSmoke 
 
> lminSmoke=LFDietStatins$Smoke - 0 
> lminSmoke 
 
> LTGSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lmaxSmoke, data=LFDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> LTGSmokemax 
 
> LTGSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference, 
Smoke, sep =",")) 
> MTGSmokemin 
 
> LCholSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=lmaxSmoke, data=LFDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> LCholSmokemax 
 
> LCholSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference, 




> LLDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods= lmaxSmoke, data=LFDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> LLDLSmokemax 
 
> LLDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference, 
Smoke, sep =",")) 
> LLDLSmokemin 
 
> LHDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods= lmaxSmoke, data=LFDietStatins, method="REML", slab= 
paste(Reference, Smoke, sep =",")) 
> LHDLSmokemax 
 
> LHDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference, 
Smoke, sep =",")) 
> LHDLSmokemin 
 
#Min Max for Fat Intake 
> lmaxfat = .30 -LFDietStatins$Fat 
> lmaxfat 
 
> lminfat=LFDietStatins$Fat - .17 
> lminfat 
 
> LTGfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
lmaxfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep 
=",")) 
> LTGfatmax  
 
> LTGfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LCholfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LCholfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LLDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 





> LLDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 




> LHDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




> LHDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 




#Min Max for Carbohydrate Intake 
> lmaxcarb = .67 -LFDietStatins$Carbs 
> lmaxcarb 
 
> lmincarb=LFDietStatins$Carbs - .421 
> lmincarb 
> LTGcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LTGcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LCholcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LCholcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LLDLcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 




> LLDLcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lmincarb, data=LFDietStatins, method="REML", slab= paste(Reference, 




> LHDLcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




> LHDLcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




#Min Max for Protein Intake 
> lmaxpro = .21 -LFDietStatins$Protein 
> lmaxpro 
 
> lminpro=LFDietStatins$Protein - .15 
> lminpro 
 
> LTGpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LTGpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference, 
Protein, sep =",")) 
> LTGpromin 
 
> LCholpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LCholpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference, 
Protein, sep =",")) 
> LCholpromin 
 
> LLDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 




> LLDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference, 
Protein, sep =",")) 
> LLDLpromin 
 
> LHDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 





> LHDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference, 
Protein, sep =",")) 
> LHDLpromin 
 
#Min Max for Intervention Group Size 
> lintgrpmax = 753 -LFDietStatins$n_post 
> lintgrpmax 
 
> lintgrpmin =LFDietStatins$n_post - 12 
> lintgrpmin 
 
> LTGintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference, 
n_post, sep =",")) 
> LTGintgrpmax 
 
> LTGintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LCholintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference, 
n_post, sep =",")) 
> LCholintgrpmax 
 
> LCholintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LLDLintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference, 
n_post, sep =",")) 
> LLDLintgrpmax 
 
> LLDLintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lintgrpmin, data=LFDietStatins, method="REML", slab= paste(Reference, 
n_post, sep =",")) 
> LLDLintgrpmin 
 
> LHDLintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference, 




> LHDLintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




#Min Max for Total Sample Size 
> lNmax = 3390 -LFDietStatins$Ntotal 
> lNmax 
 
> lNmin =LFDietStatins$Ntotal - 19 
> lNmin 
 
> LTGNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LTGNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LCholNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LCholNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LLDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 




> LLDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), 
mods=lNmin, data=LFDietStatins, method="REML", slab= paste(Reference, 
Ntotal, sep =",")) 
> LLDLNmin 
 
> LHDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




> LHDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 





#Min Max for Number of Intervention Groups 
>lmaxintgrp = 5 - LFDietStatins$NoIntGrps 
> lmaxintgrp 
 
> lminintgrp = LFDietStatins$NoIntGrps - 1 
> lminintgrp 
 
> LTGintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LTGintgrp1max 
 
> LTGintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LTGintgrp1min 
 
> LCholintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods= lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LCholintgrp1max 
 
> LCholintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), 
mods= lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LCholintgrp1min 
 
> LDLintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LDLintgrp1max 
 
> LDLintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LDLintgrp1min 
 
> LHDLintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods= lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LHDLintgrp1max 
 
> LHDLintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods= lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference, 
NoIntGrps, sep =",")) 
> LHDLintgrp1min 
 
#Min Max for Number of Subjects with Cardiovascular Disease 




> lmincvd = LFDietStatins$CVDNo - 5 
> lmincvd 
 
> LTGcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LTGcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 




> LCholcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LCholcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 




> LDLcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 




> LDLcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 




> LHDLcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




> LHDLcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 




#Min Max for Cholesterol Intake 
>lmaxchol = 300 - LFDietStatins$Cholesterol 
> lmaxchol 
 




> LTGcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LTGcholmax 
 
> LTGcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= 
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LTGcholmin 
 
> LCholcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LCholcholmax 
 
> LCholcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods= 
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LCholcholmin 
 
> LDLcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LDLcholmax 
 
> LDLcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods= 
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LDLcholmin 
 
> LHDLcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LHDLcholmax 
 
> LHDLcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods= 
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference, 
Cholesterol, sep =",")) 
> LHDLcholmin 
 
#Provision of Food 
> LTGProv1<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Provision==1), data= LFDietStatins, method="REML", 
slab=paste(Reference, Provision, sep “,”)) 
> LTGProv1 
 
> LCholProv1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(Provision==1), data= LFDietStatins, method="REML", 




> LLDLProv1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(Provision==1), data= LFDietStatins, method="REML", 
slab=paste(Reference, Provision, sep “,”)) 
> LLDLProv1 
 
> LHDLProv1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(Provision==1), data= LFDietStatins, method="REML", 
slab=paste(Reference, Provision, sep “,”)) 
> LHDLProv1 
 
#No Provision of Food 
> LTGProv0<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), 
mods=(Provision==0), data= LFDietStatins, method="REML" 
slab=paste(Reference, Provision, sep “,”)) 
> LTGProv0 
 
> LCholProv0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), 
mods=(Provision==0), data= LFDietStatins, method="REML" 
slab=paste(Reference, Provision, sep “,”)) 
> LCholProv0 
 
> LLDLProv0<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), 
mods=(Provision==0), data= LFDietStatins, method="REML", 
slab=paste(Reference, Provision, sep “,”)) 
> LLDLProv0 
 
> LHDLProv0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), 
mods=(Provision==0), data= LFDietStatins, method="REML", 





#Length of Intervention 
LCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Weeks, 
data=LFDietStatins, method="REML", slab= paste(Reference, Weeks, sep =",")) 
LCholwkspred <- predict(LCholwks, newmods=cbind(seq(0,104,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietTChol= subset(LFDietStatins,Diet==5 & Outcome==2) #Here we have to 
create the 
subsample we are working on to just plot the observed values of that below 
plot(dietTChol$Weeks,dietTChol$d.ex.,pch= 20, col="black", bg = "black", 
cex=size, 
xlab = "Number of Weeks", #Plotting here the observed values of the subsample 
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 104), ylim=c(-3, 0.5)) 
lines(seq(0,104,.1), LCholwkspred$pred, col = "dark red") 
lines(seq(0,104,.1), LCholwkspred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,104,.1), LCholwkspred$ci.ub, lty = "dashed", col="dark red") 
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LCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = 
Weeks, 
data=LFDietStatins, method="REML", slab= paste(Author, Year, sep =",")) 
LCholwkspred <- predict(LCholwks, newmods=cbind(seq(0,104,.1))) 
LCholwks 
 
LLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Weeks, 
data=LFDietStatins, method="REML", slab= paste(Reference, Weeks, sep =",")) 
LLDLwkspred <- predict(LLDLwks, newmods=cbind(seq(0,104,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3) 
plot(dietLDL$Weeks,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Number of Weeks", #Plotting here the observed values of the subsample 
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 104), ylim=c(-3, 0.5)) 
lines(seq(0,104,.1), LLDLwkspred$pred, col = "dark red") 
lines(seq(0,104,.1), LLDLwkspred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,104,.1), LLDLwkspred$ci.ub, lty = "dashed", col="dark red") 
LLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = 
Weeks, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LLDLwkspred <- predict(LLDLwks, newmods=cbind(seq(0,104,.1))) 
LLDLwks 
 
#Proportion of Females 
LCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Female, 
data=LFDietStatins, method="REML", slab= paste(Reference, Female, sep =",")) 
LCholfempred <- predict(LCholfem, newmods=cbind(seq(0,1.0,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2) 
plot(dietChol$Female,dietChol$d.ex.,pch= 20, col="black", bg = "black", 
cex=size, 
xlab = "Proportion of Female", #Plotting here the observed values of the 
subsample 
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 1.0), ylim=c(-3, 0.5)) 
lines(seq(0,1.0,.1), LCholfempred$pred, col = "dark red") 
lines(seq(0,1.0,.1), LCholfempred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,1.0,.1), LCholfempred$ci.ub, lty = "dashed", col="dark red") 
LCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = 
Female, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LCholfempred <- predict(LCholfem, newmods=cbind(seq(0,1.0,.1))) 
LCholfem 
 
LLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Female, 
data=LFDietStatins, method="REML", slab= paste(Reference, Female, sep =",")) 
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LLDLfempred <- predict(LLDLfem, newmods=cbind(seq(0,1.0,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3) 
plot(dietLDL$Female,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Proportion of Female", #Plotting here the observed values of the 
subsample 
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 1.0), ylim=c(-3, 0.5)) 
lines(seq(0,1.0,.1), LLDLfempred$pred, col = "dark red") 
lines(seq(0,1.0,.1), LLDLfempred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,1.0,.1), LLDLfempred$ci.ub, lty = "dashed", col="dark red") 
LLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = 
Female, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LLDLfempred <- predict(LLDLfem, newmods=cbind(seq(0,1.0,.1))) 
LLDLfem 
 
#Recommended Proportion of Fat Intake 
LCholfat<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Fat, 
data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep =",")) 
LCholfatpred <- predict(LCholfat, newmods=cbind(seq(0,1.0,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2) 
plot(dietChol$Fat,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Proportion of Fat Intake", #Plotting here the observed values of the 
subsample 
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0.1, 0.35), ylim=c(-3.5, 0.5)) 
lines(seq(0,1.0,.1), LCholfatpred$pred, col = "dark red") 
lines(seq(0,1.0,.1), LCholfatpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,1.0,.1), LCholfatpred$ci.ub, lty = "dashed", col="dark red") 
LCholfat<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = Fat, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LCholfatpred <- predict(LCholfat, newmods=cbind(seq(0,1.0,.1))) 
LCholfat 
 
#Proportion of Carbohydrate Intake 
LCholcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Carbs, 
data=LFDietStatins, method="REML", slab= paste(Reference, Carbs, sep =",")) 
LCholcarbpred <- predict(LCholcarb, newmods=cbind(seq(0,1.0,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2) 
plot(dietChol$Carbs,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Proportion of Carbohydrate Intake",  
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ylab = "Total Cholesterol Effect Size (d)", xlim=c(0.1, 0.7), ylim=c(-3, 0.5)) 
lines(seq(0,1.0,.1), LCholcarbpred$pred, col = "dark red") 
lines(seq(0,1.0,.1), LCholcarbpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,1.0,.1), LCholcarbpred$ci.ub, lty = "dashed", col="dark red") 
LCholcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = 
Carbs, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LCholcarbpred <- predict(LCholcarb, newmods=cbind(seq(0,1.0,.1))) 
LCholcarb 
 
LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Carbs, 
data=LFDietStatins, method="REML", slab= paste(Reference, Carbs, sep =",")) 
LLDLcarbpred <- predict(LLDLcarb, newmods=cbind(seq(0,1.0,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3) 
plot(dietLDL$Carbs,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Proportion of Carbohydrate Intake",  
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0.25, 0.7), ylim=c(-3, 0.5)) 
lines(seq(0,1.0,.1), LLDLcarbpred$pred, col = "dark red") 
lines(seq(0,1.0,.1), LLDLcarbpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,1.0,.1), LLDLcarbpred$ci.ub, lty = "dashed", col="dark red") 
LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = Carbs, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LLDLcarbpred <- predict(LLDLcarb, newmods=cbind(seq(0,1.0,.1))) 
LLDLcarb 
 
#Recommended Proportion of Protein Intake 
LHDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=Protein, 
data=LFDietStatins, method="REML", slab= paste(Reference, Protein, sep =",")) 
LHDLpropred <- predict(LHDLpro, newmods=cbind(seq(0,1.0,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4) 
plot(dietHDL$Protein,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Proportion of Protein Intake",  
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0.10, 0.30), ylim=c(-1, 1.5)) 
lines(seq(0,1.0,.1), LHDLpropred$pred, col = "dark red") 
lines(seq(0,1.0,.1), LHDLpropred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,1.0,.1), LHDLpropred$ci.ub, lty = "dashed", col="dark red") 
LHDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods = 
Protein, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LHDLpropred <- predict(LHDLpro, newmods=cbind(seq(0,1.0,.1))) 
LHDLpro 
 
#Intervention Group Size 
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LTGint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =",")) 
LTGintpred <- predict(LTGint, newmods=cbind(seq(0,753,1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietTG= subset(LFDietStatins,Diet==5 & Outcome==1) 
plot(dietTG$n_post,dietTG$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Intervention Group Size",  
ylab = "Triglycerides Effect Size (d)", xlim=c(0, 760), ylim=c(-3.5, 0.5)) 
lines(seq(0,753,1), LTGintpred$pred, col = "dark red") 
lines(seq(0,753,1), LTGintpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,753,1), LTGintpred$ci.ub, lty = "dashed", col="dark red") 
LTGint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods = n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LTGintpred <- predict(LTGint, newmods=cbind(seq(0,753,.1))) 
LTGint 
 
LCholint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =",")) 
LCholintpred <- predict(LCholint, newmods=cbind(seq(0,753,1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2) 
plot(dietChol$n_post,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Intervention Group Size",  
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 760), ylim=c(-3.5, 0.5)) 
lines(seq(0,753,1), LCholintpred$pred, col = "dark red") 
lines(seq(0,753,1), LCholintpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,753,1), LCholintpred$ci.ub, lty = "dashed", col="dark red") 
LCholint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LCholintpred <- predict(LCholint, newmods=cbind(seq(0,753,1))) 
LCholint 
 
LLDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =",")) 
LLDLintpred <- predict(LLDLint, newmods=cbind(seq(0,753,1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3) 
plot(dietLDL$n_post,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Intervention Group Size",  
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 800), ylim=c(-3.5, 0.5)) 
lines(seq(0,753,1), LLDLintpred$pred, col = "dark red") 
lines(seq(0,753,1), LLDLintpred$ci.lb, lty = "dashed", col="dark red") 
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lines(seq(0,753,1), LLDLintpred$ci.ub, lty = "dashed", col="dark red") 
LLDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LLDLintpred <- predict(LLDLint, newmods=cbind(seq(0,753,1))) 
LLDLint 
 
LHDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =",")) 
LHDLintpred <- predict(LHDLint, newmods=cbind(seq(0,753,1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4) 
plot(dietHDL$n_post,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Intervention Group Size",  
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 800), ylim=c(-1, 1.5)) 
lines(seq(0,753,1), LHDLintpred$pred, col = "dark red") 
lines(seq(0,753,1), LHDLintpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,753,1), LHDLintpred$ci.ub, lty = "dashed", col="dark red") 
LHDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods = n_post, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LHDLintpred <- predict(LHDLint, newmods=cbind(seq(0,753,.1))) 
LHDLint 
 
#Number with Cardiovascular Disease 
LCholcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=CVDNo, 
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =",")) 
LCholcvdpred <- predict(LCholcvd, newmods=cbind(seq(0,113,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2) 
plot(dietChol$CVDNo,dietChol$d.ex.,pch= 20, col="black", bg = "black", 
cex=size, 
xlab = "Number of Subjects with Cardiovascular Disease",  
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 115), ylim=c(-4, 0.5)) 
lines(seq(0,113,.1), LCholcvdpred$pred, col = "dark red") 
lines(seq(0,113,.1), LCholcvdpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,113,.1), LCholcvdpred$ci.ub, lty = "dashed", col="dark red") 
LCholcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = 
CVDNo, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LCholcvdpred <- predict(LCholcvd, newmods=cbind(seq(0,113,.1))) 
LCholcvd 
 
LLDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=CVDNo, 
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =",")) 
LLDLcvdpred <- predict(LLDLint, newmods=cbind(seq(0,113,1))) 




size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3) 
plot(dietLDL$CVDNo,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Number of Subjects with Cardiovascular Disease",  
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 115), ylim=c(-4, 0.5)) 
lines(seq(0,113,.1), LLDLcvdpred$pred, col = "dark red") 
lines(seq(0,113,.1), LLDLcvdpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,113,.1), LLDLcvdpred$ci.ub, lty = "dashed", col="dark red") 
LLDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = 
CVDNo, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LLDLcvdpred <- predict(LLDLcvd, newmods=cbind(seq(0,1.0,.1))) 
LLDLcvd 
 
LHDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=CVDNo, 
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =",")) 
LHDLcvdpred <- predict(LHDLcvd, newmods=cbind(seq(0,113,.1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4) 
plot(dietHDL$CVDNo,dietHDL$d.ex.,pch= 20, col="black", bg = "black", 
cex=size, 
xlab = "Number of Subjects with Cardiovascular Disease",  
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 115), ylim=c(-1, 1.5)) 
lines(seq(0,113,.1), LHDLcvdpred$pred, col = "dark red") 
lines(seq(0,113,.1), LHDLcvdpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,113,.1), LHDLcvdpred$ci.ub, lty = "dashed", col="dark red") 
LHDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods = 
CVDNo, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LHDLcvdpred <- predict(LHDLcvd, newmods=cbind(seq(0,1.0,.1))) 
LHDLcvd 
 
#Total Sample Size 
LCholN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Ntotal, 
data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep =",")) 
LCholNpred <- predict(LCholN, newmods=cbind(seq(0,3390,1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2) 
plot(dietChol$Ntotal,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Sample Size",  
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 3400), ylim=c(-4, 0.5)) 
lines(seq(0,3390,1), LCholNpred$pred, col = "dark red") 
lines(seq(0,3390,1), LCholNpred$ci.lb, lty = "dashed", col="dark red") 
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lines(seq(0,3390,1), LCholNpred$ci.ub, lty = "dashed", col="dark red") 
LCholN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = Ntotal, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LCholNpred <- predict(LCholN, newmods=cbind(seq(0,3390,.1))) 
LCholN 
 
LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Ntotal, 
data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep =",")) 
LLDLNpred <- predict(LLDLN, newmods=cbind(seq(0,3390,1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3) 
plot(dietLDL$Ntotal,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Sample Size",  
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 3400), ylim=c(-4, 0.5)) 
lines(seq(0,3390,1), LLDLNpred$pred, col = "dark red") 
lines(seq(0,3390,1), LLDLNpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,3390,1), LLDLNpred$ci.ub, lty = "dashed", col="dark red") 
LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = Ntotal, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LLDLNpred <- predict(LLDLN, newmods=cbind(seq(0,3390,.1))) 
LLDLN 
 
LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=Ntotal, 
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =",")) 
LHDLNpred <- predict(LHDLN, newmods=cbind(seq(0,3390,1))) 
wi = LFDietStatins$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4) 
plot(dietHDL$Ntotal,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size, 
xlab = "Sample Size",  
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 3400), ylim=c(-1, 1.5)) 
lines(seq(0,3390,1), LHDLNpred$pred, col = "dark red") 
lines(seq(0,3390,1), LHDLNpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,3390,1), LHDLNpred$ci.ub, lty = "dashed", col="dark red") 
LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods = Ntotal, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
LHDLNpred <- predict(LHDLN, newmods=cbind(seq(0,3390,.1))) 
LHDLN 
 
#Recommended Dietary Cholesterol Intake 
LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), 
mods=Cholesterol, 
data=LFDietStatins, method="REML", slab= paste(Reference, Cholesterol, sep 
=",")) 
LHDLcholpred <- predict(LHDLchol, newmods=cbind(seq(0,300,1))) 




size= 1.0 + 0.5 * (wi - min)/(max - min) 
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4) 
plot(dietHDL$Cholesterol,dietHDL$d.ex.,pch= 20, col="black", bg = "black", 
cex=size, 
xlab = "Dietary Cholesterol Intake (mg)",  
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 300), ylim=c(-1, 1.5)) 
lines(seq(0,300,.1), LHDLcholpred$pred, col = "dark red") 
lines(seq(0,300,.1), LHDLcholpred$ci.lb, lty = "dashed", col="dark red") 
lines(seq(0,300,.1), LHDLcholpred$ci.ub, lty = "dashed", col="dark red") 
LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods = 
Cholesterol, 
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =",")) 
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